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CHK2 IS NEGATIVELY REGULATED BY PROTEIN PHOSPHATSE 2A 
Alyson K. Freeman 
ABSTRACT 
 Checkpoint kinase 2 (CHK2) is an effector kinase of the DNA damage response 
pathway and although its mechanism of activation has been well studied, the attenuation 
of its activity following DNA damage has not been explored.  Here, we identify the B'α 
subunit of protein phosphatase 2A (PP2A), a major protein serine/threonine phosphatase 
of the cell, as a CHK2 binding partner and show that their interaction is modulated by 
DNA damage.  B'α binds to the SQ/TQ cluster domain of CHK2, which is a target of 
ATM phosphorylation.  CHK2 is able to bind to many B' subunits as well as the PP2A C 
subunit, indicating that it can bind to the active PP2A enzyme.  The induction of DNA 
double-strand breaks by ionizing radiation (IR) as well as treatment with doxorubicin 
causes dissociation of the B'α and CHK2 proteins, however, it does not have an effect on 
the binding of B'α to CHK1.  IR-induced dissociation is an early event and occurs in a 
dose-dependent manner.  CHK2 and B'α can re-associate hours after DNA damage and 
this is not dependent upon the repair of the DNA.  Dissociation is dependent on ATM 
activity and correlates with an increase in the ATM-dependent phosphorylation of CHK2 
at serines 33 and 35 in the SQ/TQ region.  Indeed, mutating these sites to mimic 
phosphorylation increases the dissociation after IR.  CHK2 is able to phosphorylate B'α 
in vitro; however, in vivo, irradiation has no effect on PP2A activity or localization.  
ix 
 
Alternatively, PP2A negatively regulates CHK2 phosphorylation at multiple sites, as well 
as its kinase activity and protein stability.  These data reveal a novel mechanism for 
PP2A to keep CHK2 inactive under normal conditions while also allowing for a rapid 
release from this regulation immediately following DNA damage. This is followed by a 
subsequent reconstitution of the PP2A/CHK2 complex in later time points after damage, 
which may help to attenuate the signal.  This mechanism of CHK2 negative regulation by 
PP2A joins a growing list of negative regulations of DNA damage response proteins by 
protein serine/threonine phosphatases.   
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INTRODUCTION 
DNA Damage Response Pathway  
 Maintenance of genomic integrity is an essential part of cellular physiology.  
Genotoxic insults that induce DNA breaks must be repaired in order to prevent the 
propagation of mutations that can contribute to malignant transformation.  DNA damage 
occurs via multiple mechanisms including ionizing radiation (IR), ultraviolet radiation 
(UV), chemicals from the environment, replication stress, and reactive oxygen species 
that are made as a byproduct of cellular metabolism.  The primary role of the DNA 
damage response (DDR) is to induce cell cycle arrest, repair the incurred DNA damage, 
or, in cases where the extent of damage is beyond repair, signal for the initiation of 
apoptosis or cellular senescence (214).   
 The different types of DNA damage as well as each repair mechanism were 
extensively reviewed recently (153).  Here, we will focus primarily on the DNA damage 
induced by IR, which causes mainly double-strand breaks (DSB), UV which causes 
single-strand breaks (SSB), and hydroxyurea (HU) which causes replication stress.  DSB 
can be repaired through non-homologous end joining (NHEJ) and homologous 
recombination (HR) (60).  The exact repair mechanism for stalled replication forks and 
SSB in mammals has not been elucidated, but in yeast, it involves a special class of DNA 
polymerases called translesion polymerases (139). 
 After a DNA break, the DDR must arrest the cell cycle to allow time for the DNA 
to be repaired.  Distinct cell cycle checkpoints include G1/S or G1, intra-S-phase, and 
2 
 
G2/M or G2.  In the case that the damage cannot be repaired, the cell cycle arrest can lead 
to senescence or the cell can signal through the apoptotic pathway (108, 130).  Signaling 
through the DDR occurs through a distinct pathway that includes sensors, signal 
transducing proteins, effector kinases, mediators, and effector proteins (Figure 1). 
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Figure 1.  The DNA damage response pathway.  DNA breaks and replication stress 
signal through the sensors (MRN and 9-1-1), mediators (H2AX, BRCA1, MDC1, 
53BP1), signal transducing kinases (ATM, ATR), effector kinases (CHK2, CHK1), and 
effector proteins (E2F1, p53, Cdc25) leading to cell cycle arrest and gene transcription.  
Proteins that are phosphorylated by ATM and/or ATR are marked by a gray phosphate 
group and proteins that are phosphorylated by CHK2 and/or CHK1 are marked by a black 
phosphate group.   An arrow signals activation and a "T" signals inhibition. 
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Sensors - Mre11-Rad50-Nbs1 and Rad9-Rad1-Hus1 Complexes 
 DNA damage is recognized by sensor proteins that initiate the activation of the 
DDR.  These sensors include the Mre11-Rad50-Nbs1 (MRN) complex and the Rad9-
Rad1-Hus1 (9-1-1) complex that localize to DSB or regions of replication stress and SSB, 
respectively (84, 139).  These complexes are necessary for the activation of the signal 
transducing kinases. 
 The structure of the 9-1-1 complex resembles the proliferating cell nuclear 
antigen (PCNA) sliding clamp that is loaded onto DNA at points of replication (139).  
The Rad17-replication factor C (RFC) complex acts as the 9-1-1 clamp loader in a 
process analogous to RFC acting as the clamp loader for PCNA (11).   
 The MRN complex binds to DNA DSB.  Mre11 binds to Nbs1, DNA, and Rad50 
and possesses DNA exonuclease, endonuclease, and unwinding activities (196).  Rad50 
may function to keep the broken ends of the DNA together.  Nbs1 functions to recruit 
signal transducing kinases to the break site and mediates the DDR signal (215). 
  
Signal Transducing Kinases - ATM and ATR 
 The localization of the MRN and 9-1-1 complexes to the sites of DNA damage 
signals to the signal transducing kinases to become active.  These kinases are Ataxia-
telangiectasia mutated (ATM) and ATM and Rad3-related (ATR), which are members of 
the PI-3K like kinase (PIKK) family with DNA-dependent protein kinase (DNA-PK). 
 Primarily in response to DSB, ATM is activated by autophosphorylation on 
S1981 causing inactive dimers to dissociate into active monomers (7).  Interestingly, the 
ATM protein was first identified in patients with ataxia-telangiectasia (AT) (156).  AT 
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causes genomic instability, a predisposition to cancer, immunodeficiency, and several 
neurological impairments (33).  Mutation of Mre11 and Nbs1 in humans causes the 
similar disorders AT-like disorder (ATLD) and Nijmegen Breakage Syndrome (NBS), 
respectively (172, 188).  Nbs1 seemingly acts both upstream and downstream of ATM as 
ATM is known to phosphorylate Nbs1 on S343 and at the same time Nbs1 and the MRN 
complex have been shown to be required for full activation of ATM (81, 186, 215). 
 The localization of ATR to the break site and its subsequent activation is 
dependent upon the 9-1-1 complex, binding between ATR and ATR-interacting protein 
(ATRIP), and replication protein A (RPA).  RPA coats single-strand DNA and consists of 
3 subunits: RPA70, RPA32, and RPA14 (29).  RPA32 is phosphorylated at T21 and S33 
by ATM , ATR, and DNA-PK (12). 
 Although DNA-PK is not classified as a signal transducing kinase, it does play a 
role in the DDR.  DNA-PK is comprised of a catalytic subunit, DNA-PKcs, and the 
targeting subunit, the Ku70-Ku80 heterodimer.  It is activated upon association with 
DNA (165).  The primary role of DNA-PK is to initiate NHEJ to repair DNA double-
strand breaks.  Two major autophosphorylation clusters in DNA-PKcs (referred to as 
ABCDE and PQR) regulate the ability of DNA-PK to function in DNA end processing 
during repair (117).   
 
Effector Kinases - CHK1 and CHK2 
 The signal transducing kinases ATM and ATR signal through the effector kinases 
CHK1 and CHK2 (checkpoint kinase 1 and checkpoint kinase 2) (8).  CHK1 and CHK2 
work alongside ATM and ATR to perpetuate the DDR signal.  CHK2 is activated 
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primarily in response to DSB through the phosphorylation of T68 by ATM (3, 113, 119).  
CHK1 is active even in unperturbed cells, but is also further activated through the 
phosphorylation of S317 and S345 by ATR, primarily in response to SSB and replication 
stress (8).  Interestingly, there is also crosstalk between these two pathways.  The 
processing of DSB in an ATM- and Mre11-dependent manner leads to RPA coating the 
single-stranded DNA, leading to activation of ATR and CHK1 (73).  ATR can 
phosphorylate and activate ATM following UV treatment or replication stress (174).  
CHK1 S317 phosphorylation has been shown to be dependent on ATM and Nbs1 in 
addition to ATR (53).   
 The importance of the effector proteins in development has been discovered using 
mouse models.  CHK1-deficient mice are embryonic lethal, however, CHK2-deficienct 
mice are viable and do not have an increased risk for cancer (68, 100, 181, 182).  This, 
along with the fact that CHK1 is active under normal circumstances, leads some to the 
belief that CHK1 acts as the "workhorse" of the cells and CHK2 functions only when 
needed after DNA damage. 
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Mediators - H2AX, BRCA1, MDC1, and 53BP1 
 The mediator proteins H2AX, BRCA1, MDC1, and 53BP1 work to coordinate the 
localization of various factors in the DDR, promote their activation, and regulate 
substrate accessibility (176). 
 The histone variant H2AX comprises 10-15% of total cellular histone H2A, as 
revealed through mouse studies (19).  H2AX is phosphorylated by ATM, ATR, and 
DNA-PK on S139 and is commonly referred to as γ-H2AX (148).  γ-H2AX forms foci 
both proximal and distal to the DSB site and is dephosphorylated following repair of the 
DNA (reviewed in a following section), thus it is an excellent marker for the presence of 
DSB (147).  γ-H2AX is required for the foci formation of Nbs1 and the other mediator 
proteins BRCA1, MDC1, and 53BP1, which is important for DDR signaling (9, 19, 140, 
173, 178).   
 BRCA1 (breast cancer susceptibility 1) is phosphorylated by ATM on S1387 and 
by CHK2 on S988 in response to IR (21, 32, 52).  In response to UV, BRCA1 is 
phosphorylated by ATR on S1457 (54).  Phosphorylated BRCA1 forms distinct nuclear 
foci that co-localize with γ-H2AX, MDC1, and the MRN complex.  The role of BRCA1 
seems to be to direct repair through both NHEJ and HR (166, 192). 
 MDC1 is phosphorylated in an ATM- and CHK2-dependent manner, binds to γ-
H2AX and co-localizes with γ-H2AX foci, and is required for the formation of MRN, 
BRCA1, and 53BP1 foci (103, 173, 177).  Thus, MDC1 functions as a molecular scaffold 
to mediate parts of the DDR downstream of foci formation (126). 
 53BP1 was first discovered based on its ability to bind to the DNA-binding 
domain of p53 (70).  In the DDR, 53BP1 localizes to the sites of DSB, is required for cell 
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cycle checkpoints, and is required for p53 accumulation and BRCA1 foci formation 
(190).  It seems to be involved in ATM activation, although the precise mechanism is not 
known (125). 
 
Effector Proteins - Cdc25, E2F1, and p53 
 The effector proteins Cdc25, p53 and E2F1 function to activate cell cycle 
checkpoints and regulate the transcription of genes whose products are important in the 
end result of the DDR, whether it be DNA repair, apoptosis, or senescence. 
 The Cdc25 phosphatases regulate progression through the cell cycle by removing 
inhibitory Y15 phosphatases from the cyclin-dependent kinases Cdk1 and Cdk2 (38).  
The negative regulation of Cdc25 leads to G1/S, intra-S, and G2/M checkpoints.  CHK1 
phosphorylates Cdc25A on S76, leading to Cdc25A ubiquitination and degradation (74).  
CHK1 and CHK2 phosphorylate Cdc25C on S216 which allows 14-3-3 binding and 
subsequent sequestration of Cdc25C in the cytoplasm, away from substrates.  Cdc25B1 
and Cdc25B2 are phosphorylated on S309 and S323, respectively, leading to inactivation 
through the same 14-3-3-mediated mechanism (38, 210). 
 The transcription factor p53 may be the most widely recognized tumor suppressor 
and has been found to be mutated in more than half of all tumor cases (62).  In addition, 
the multi-organ cancer syndrome, Li-Fraumeni syndrome, is caused in most cases to be 
from inheritance of a mutant copy of the p53 gene, TP53, and subsequent loss of the 
wild-type copy (109, 170). 
 P53 is stabilized in the DDR which allows it to activate the transcription of genes 
whose products participate in cell cycle arrest, DNA repair, senescence, or apoptosis, 
9 
 
depending upon the cellular stress (63).  Mdm2 negatively regulates p53 through 
ubiquitin-mediated proteosomal degradation (64, 69, 78).  MdmX also negatively 
regulates p53 by binding to Mdm2 and enhancing Mdm2 binding to and ubiquitination of 
p53 (98, 143, 185).  ATM, ATR, DNA-PK, CHK1 and CHK2 stabilize p53 by direct 
phosphorylation on S15 and S20 which prevent p53 binding to Mdm2 (5, 160, 161).  
ATM and ATR inhibit Mdm2 by phosphorylating it on S395 and S407, respectively (114, 
162).  ATM phosphorylates MdmX on S403 which leads to its ubiquitination and 
degradation (141).  CHK2 phosphorylates MdmX on S367 and S342 which promotes 14-
3-3 binding and degradation of MdmX (24, 82).  Therefore, multiple DDR proteins 
coordinate to stabilize and activate p53 through phosphorylation of p53 and its negative 
regulators Mdm2 and MdmX. 
 The transcription factor E2F1 is also activated in the DDR.  ATM and CHK2 
phosphorylate E2F1 on S31 and S364, respectively, which leads to E2F stabilization (97, 
171).  E2F1 can then upregulate genes that lead to cell cycle checkpoints or apoptosis, 
although the specific genes that are responsible for these cellular effects have not yet 
been determined. 
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Checkpoint Kinase CHK2 
 The functions of CHK2 in phosphorylating and activating factors in the DDR are 
outlined above.  This section will focus on the details of CHK2 structure and activation, 
its mutations found in cancer, and the pursuit of a CHK2 cellular phenotype. 
 
CHK2 Structure and Activation 
 CHK2 contains three major domains (Figure 2): an SQ/TQ domain (amino acid 
residues 19-69), an FHA domain (amino acid residues 112-175), and a serine/threonine 
kinase domain (amino acid residues 220-486), all of which play a role in the activation of 
CHK2.  The SQ/TQ domain contains seven serine or threonine residues followed by a 
glutamic acid.  SQ and TQ sites are preferentially phosphorylated by ATM and ATR (77, 
132).  The FHA domain recognizes and binds to phosphorylated proteins and therefore 
mediates protein-protein interactions (41).  The kinase domain is the enzymatically active 
domain and is responsible for the phosphorylation of serine and threonine residues of 
CHK2 substrates. 
 Under normal conditions, CHK2 exists as a monomer (2).  In response to DNA 
damage, ATM phosphorylates CHK2 on T68 in the SQ/TQ domain (3, 113, 119).  The 
FHA domain of one molecule of CHK2 binds to the phosphorylated T68 of another, 
allowing autophosphorylation of T383 and T387 within the kinase domain (83, 200). 
CHK2 then dissociates into active monomers (2).  CHK2 is also phosphorylated at 
serines 19, 33, and 35 in the SQ/TQ domain by ATM and autophosphorylated at S516 
and these events enhance CHK2 activity (16, 79, 124, 198).  Phosphorylation of CHK2 at 
S456 regulates CHK2 stability and autophosphorylation at S379 leads to CHK2 
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ubiquitination and positively affects CHK2 function (75, 104).  Of note, a useful tool in 
studying CHK2 has been the D347A dominant negative kinase-dead mutant (22, 112). 
 The crystal structures of the FHA and kinase domains, alone and together, have 
been solved, which has proven extremely informative for deciphering the specific 
residues necessary for the oligomerization and activation of CHK2 as well as binding 
between CHK2 and its substrates (17, 95, 137).  Attempts to crystallize full length CHK2 
have been unsuccessful due to the fact that the SQ/TQ domain is highly susceptible to 
digestions, suggesting that it is unstructured or loosely folded (17).  In order to crystallize 
the kinase domain of CHK2 and preserve the ability to form dimers, a small-molecular 
inhibitor or a kinase-dead mutant needed to be used, since active CHK2 dissociates into 
monomers (17, 137). 
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Figure 2.  The structure of CHK2.  The SQ/TQ domain is displayed in light gray, the 
FHA domain in dark gray, and the kinase domain in black.  Important CHK2 
phosphorylation sites are highlighted. 
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CHK2 in Cancer 
 CHK2 is considered a tumor suppressor and mutations in CHEK2, the gene 
encoding human CHK2, have been found in various cancers.  The first mutation found in 
CHEK2 was 1100delC, originally identified in families with Li-Fraumeni syndrome that 
did not have mutations in TP53 (10).  Later, this mutation was also found to be 
significantly associated with breast cancer in familial cases without a BRCA1 or BRCA2 
mutation (187).  This CHEK2 allele seems to act as a low-penetrance tumor suppressor 
gene and may be an adverse indicator of prognosis (34, 118).  The SUM102PT breast 
cancer cell line contains the 1100delC mutation (195). 
 Many other mutations in CHK2 have also been identified, but the clinical 
significance of most are not yet clear.  I157T and 1422delT were found in Li-Fraumeni 
families lacking a TP53 mutation (10).  R180H, R117G, R137Q, and delE161 were 
identified in breast cancer patients with familial history (167, 168).  Y424H and S428F 
were found in Ashkenazi Jewish families with a high risk of breast cancer (80, 159).  
R145W was identified in the HCT15 colon carcinoma cell line (10).  The nucleotide 
mutation T908A was found in the UACC812 breast cancer cell line (195).  In addition, 
multiple germline CHEK2 mutations have been found in prostate cancer patients and 
families with familial prostate cancer (37).  CHK2 transcriptional downregulation due to 
promoter methylation has also been identified in human cancers (191, 212). 
 The 1100delC mutation causes a frameshift at amino acid T366 and the 1422delT 
causes a frameshift at amino acid R475, both of which result in an early stop codon (10).  
These mutants have no kinase activity in vitro (199).  The T908A mutation also causes an 
early stop codon at L303 (195).  R145W has reduced kinase activity in vitro, is not 
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phosphorylated at T68, cannot be activated in response to IR, and cannot bind to p53 in 
vivo (46, 199).  The R145W mutation also leads to a destabilization and degradation of 
the CHK2 protein (85).  I157T cannot bind to p53 in vivo, has reduced kinase activity in 
vitro, and has deficiencies in CHK2 oligomerization and autophosphorylation (46, 158, 
199).  This is most likely due to the fact that this site plays an integral role in the FHA-
kinase domain interface during CHK2 activation (17).  1100delC and E161del are 
unstable and not efficiently phosphorylated at T68 following IR whereas R117G is 
phosphorylated at T68 but does not display a mobility shift via Western blot, suggesting 
it is not phosphorylated fully at other sites that are necessary for the activation of CHK2 
(169).  S428F could not complement a Rad53 (CHK2 homologue) deletion in S. 
cerevisiae and therefore is thought to abrogate CHK2 function (159).  R117G, R145W, 
and E161del are likely to be deleterious to CHK2 function based on a bioinformatics 
analysis of CHK2 peptides from nine species (169).   
 The germline mutations 1100delC and R145W are associated with loss of the 
wild-type allele (85).  The HCT15 cell line, which harbors the R145W mutation on one 
CHEK2 allele, has heterozygous inactivation of CHK2 (85).  Using reverse transcriptase-
PCR, the only detectable CHEK2 gene in the HCT15 cell line harbored the mutation 
which causes the expression of the R145W protein and therefore, HCT15 cells lack 
functional CHK2 (46).  The SUM102PT and UACC812 breast cancer cell lines also lack 
detectable CHK2 protein levels (195). 
 In summary, mutations in CHK2 have been found that affect protein function in a 
number of ways.  Many mutations have been identified in Li-Fraumeni families, primary 
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human cancers, and cancer cell lines, although more work needs to be done to elucidate 
the effects on CHK2 function as well as the clinical significance of these mutations.    
 
CHK2 Phenotypes 
 Two CHK2-/- mouse models have given much information about the importance 
of CHK2 in specific aspects of the DDR.  Surprisingly, given the many actions of CHK2, 
it was not found to be necessary for organism development, whereas CHK1-null mice are 
embryonic lethal (68, 100, 181, 182).   It is possible that since CHK2 and CHK1 share 
many targets, the absence of CHK2 may be compensated for by CHK1.  Here, the 
phenotypes of cells lacking CHK2 will be discussed.  
 In one CHK2 mouse model, CHK2-/- MEFs (mouse embryonic fibroblasts) and 
ES (embryonic stem) cells in a C57BL/6 background displayed a normal G2/M 
checkpoint following IR.  Initiation of the G1/S checkpoint was intact but cells were 
deficient in maintenance of the checkpoint (181).  In contrast, in another mouse model, 
thymocytes from CHK2-/- mice in the same background displayed a decrease in G1/S 
arrest, G2/M arrest, and apoptosis following IR (68).   
 Using HCT15 cells expressing HA-tagged CHK2, CHK2 was shown to play an 
integral role in the intra-S-phase checkpoint (47).  Cells lacking functional CHK2 
continued to replicate DNA after DSB instead of activating an intra-S-phase checkpoint 
in a phenotype called radioresistant DNA synthesis (RDS).  This is due to the inability to 
induce the degradation of Cdc25A.     
 Surprisingly, CHK2 was found to be not required for the p53-mediated DDR 
response.  Knockdown of CHK2 in HCT116 cells inhibited Cdc25C phosphorylation at 
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S216 but had no effect on p53 stabilization or phosphorylation on S20 following 
neocarzinostatin (NCS) treatment, which causes DSB (1).  CHEK2 in the HCT116 cell 
line was disrupted using gene targeting (71).  HCT116 CHK2-/- cells displayed normal 
p53 accumulation and phosphorylation at S20 in response to IR, intact G1/S and G2/M 
checkpoints following IR, and an appropriate apoptotic response to 5-fluorouracil when 
compared to the HCT116 wild-type cells.  Gene targeting was also used to generate 
CHK2-deficient chicken DT40 cells (144).  These cells prematurely entered mitosis 
following IR and therefore were defective in the G2/M checkpoint. 
 These often contradictory results demonstrate the difficulties in clearly 
demonstrating a cellular phenotype for cells lacking CHK2.  CHK2 function appears to 
be dependent on cell type and mechanism of induction of DNA damage.  In the literature, 
the function of CHK2 in cells is often measured by RDS, apoptosis, and the G1/S and 
G2/M checkpoints. 
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Protein Serine/Threonine Phosphatases 
 There are two major families of protein serine/threonine phosphatases (PSP).  The 
phosphoprotein phosphatases (PPP) include protein phosphatases (PP) PP1, PP2A, PP2B, 
PP4, PP5, PP6, and PP7 and the metal-dependent protein phosphatases (PPM) include 
PP2C. 
 Four isoforms of PP1 are derived from three genes and PP1 is regulated by 
interactions with many proteins (189).  PP2A consists of an A structural subunit, a C 
catalytic subunit, and one of many B regulatory subunits, described in detail in the 
following section.  PP4 and PP6 are closely related to PP2A C.  The holoenzyme of PP6 
is proposed to consist of the PP6 catalytic subunit, a SAPS subunit and an ankyrin repeat 
subunit (123).  PP2B, also known as PP3 and calcineurin, and PP7 are stimulated by 
Ca2+.  PP2B consists of an A catalytic subunit and a B subunit that is related to 
calmodulin.  PP7 contains EF-hand domains (127).  PP5 is unique in the fact that it has 
three TRP domains, which mediate protein-protein interactions, and a peptidyl-prolyl cis-
trans isomerase-like domain that are not present in any other PPP (67). 
 PPM proteins require Mg2+ or Mn2+ for enzymatic activity.  There are at least 18 
genes encoding PP2C proteins.  PP2Cδ is also known as Wip1 or PMDD1.  Wip1, 
PP2Cα, PP2Cβ, and PP2Cγ have regions of high similarity (107).  
 
PP2A Structure and Regulation 
 The active PP2A holoenzyme is comprised of three subunits:  a structural A 
subunit (PR65), a catalytic C subunit, and a B subunit (Figure 3).  There are two forms of 
the A subunit, α and β, that have 87% identity (66).  There are also two forms of the C 
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subunit, α and β, which share 97% identity (175).  The B subunits can be divided into 
four major families: the B (PR55), B' (PR61/B56), B'' (PR72), and B''' 
(PR93/PR110/striatins).  These regulatory subunits are transcribed from 15 genes that 
encode at least 26 differentially spliced isoforms (42).  The B subunits are thought to 
confer to PP2A its functional specificity (189).   
 The crystal structure of the holoenzyme containing PP2A Aα, Cα, and B'γ1 was 
solved, revealing the active enzyme structure as well as binding sites between the three 
subunits (25, 201).  The Aα subunit contains 15 HEAT repeats of antiparallel α-helices 
and forms a horseshoe shape.  The Cα subunit forms a compact ellipsoidal structure.  The 
B'γ1 subunit forms a shape similar to the Aα subunit and is comprised of 18 α-helices 
and 8 pseudo-HEAT repeats. 
 The full B' family was originally cloned in 1995 and is comprised of five genes, 
two of which are differentially spliced to form three isoforms each (116).  The names of 
all of the B' family members are as follows: B'α, B'β, B'ε, B'δ1, B'δ2, B'δ3, B'γ1, B'γ2, 
and B'γ3.  Although this nomenclature is the most commonly used, some laboratories use 
older nomenclature for certain B' proteins, using the same Greek letters, but these names 
do not match up with the current naming system.  Therefore, the literature of the B' 
family can often be confusing.  In this document, we will only refer to the most common 
naming for uniformity and therefore it may differ from the terminology used in the 
original publications. 
 Various mechanisms of PP2A activity regulation have been discovered.  
Phosphorylation of PP2A C at Y307 results in inactivation of the enzyme (23).  
Methylation of the PP2A C subunit at L309 regulates binding to the B family members, 
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but not B' or B'' proteins, which likely affects PP2A substrate specificity (102).  The 
serine/threonine kinase PKR phosphorylates B'α and this increases PP2A activity in vitro 
(202).  Therefore, in addition to substrate specificity based on the B subunit in the 
holoenzyme, post-translational modifications can affect PP2A activity. 
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Figure 3.  PP2A holoenzyme structure.  The A structural subunit binds to the C 
catalytic subunit and one of many B regulatory subunits to form a holoenzyme complex.  
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PP2A Function 
 The PP2A C subunit is an abundant protein, making up 0.1% of total cellular 
protein (189).  PP2A participates in diverse cellular processes such as differentiation, cell 
cycle regulation, and signal transduction (72).  A few key roles of PP2A, focusing on the 
role of the B' family, will be discussed here, however, an exhaustive list of proteins that 
have been shown to bind to PP2A directly can be found in a recent review (42).  The 
specific roles of PP2A in the DDR are detailed in a following section. 
 Several PP2A mouse models have illuminated the importance of PP2A in cell 
growth and embryonic development.  Knockout of the gene encoding PP2A Cα results in 
embryonic lethality (56).  Transgenic mice overexpressing B'γ in the lung die neonatally 
and lack proper lung development (45).  A dominant negative PP2A A mutant that lacks 
the ability to bind to the B subunits causes dilated cardiomyopathy and often premature 
death in transgenic mice expressing the protein in muscle (14).  
 C-Myc is transcription factor that regulates genes involved in cell growth, 
differentiation, and apoptosis.  The overexpression of c-Myc has been found in many 
human tumors (31).  PP2A containing B'α binds to c-Myc and dephosphorylates it at 
S62, resulting in decreased c-Myc protein levels and decreased c-Myc transcriptional 
activity (6).   
 PP2A has a negative effect on the G2/M transition through the negative regulation 
of Cdc25 (30, 86).  In order to achieve full activation of Cdc25C for entry into mitosis, it 
is phosphorylated at T138, which causes removal of 14-3-3.  PP2A containing B'δ 
counteracts this by dephosphorylating T138 in Cdc25C.  Chk1 phosphorylates PP2A B'δ 
at S37, enhancing B'δ binding to the A and C subunits.  Therefore, Chk1 keeps the cell 
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from progressing into mitosis by enhancing dephosphorylation of T138, keeping 14-3-3 
bound (110). 
 The apoptotic agent ceramide was shown to induce apoptosis through 
mitochondrial PP2A dephosphorylation of Bcl2 at S70, which enhances its activation 
(152).  This is mediated by the B'α subunit and ceramide promotes translocation of B'α 
to the mitochondrial membrane (151).  
 
PP2A in Cancer 
 Several independent lines of evidence suggest a role for the PP2A holoenzyme as 
a tumor suppressor and indicate the importance of inhibiting PP2A function in cellular 
transformation.  The SV40 small T antigen can bind to the PP2A A-C complex in place 
of a B subunit, inhibiting PP2A activity, and this interaction is required for SV40-
mediated transformation (61, 138, 204).  Okadaic acid (OA), a known PP2A inhibitor, 
was also found to promote tumor formation (179).   
 Somatic mutations in the gene encoding the PP2A Aβ subunit, PPP2R1B, were 
found in 15% of primary lung tumors, 15% of primary colon tumors, and 6% of lung 
tumor-derived cell lines (194).  Five missense mutations in PPP2R1B leading to amino 
acid substitutions (G15A, L499I, V498E, V500G, and S365P) were found in four colon 
carcinomas (180).  The PP2A Aα mutations E64D in a lung carcinoma, E64G in a breast 
cancer, R418W in a melanoma cell line, and a frameshift mutation at amino acid F170 in 
a breast cancer were recently identified (18).  These mutations prevent binding to the B' 
or B and C subunits (44, 150).  In addition, several cancer cell lines have reduced 
expression of the A subunit as compared to primary normal epithelial cells (216). 
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Protein Serine/Threonine Phosphatases in the DNA Damage Response 
 Phosphorylation plays an integral role in the positive and negative regulation of 
the DNA damage response pathway signaling, as described above.  Interestingly, 
phosphatases are increasingly being shown to play integral roles in the positive and 
negative regulation of the cellular signaling in response to different DNA damages.  This 
section will review the recent literature implicating the importance of phosphatases in the 
DDR alongside kinases. 
 
DNA Damage Response Proteins that are Negatively Regulated 
 Since much of the signaling of the DNA damage response pathway is regulated 
by serine and threonine phosphorylation, it is intuitive that PSPs would negatively 
regulate these phosphorylation events.  Indeed, there are many proteins that are 
negatively regulated in this manner (Figure 4). 
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Figure 4.  Protein serine/threonine phosphatases in the DNA damage response 
pathway.  The positive and negative regulation of DDR proteins via PSPs is shown.  An 
arrow indicates activation and a "T" indicates inhibition.  
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ATM and ATR 
 The first evidence that PP2A might play a role in the ATM-dependent DDR came 
from the finding that the PP2A B subunit dissociates from the PP2A heterotrimer in the 
nucleus in an ATM-dependent manner after IR (58).  It was later found that inhibition of 
PP2A with OA or expression of a dominant-negative PP2A C increased ATM 
autophosphorylation at S1981 under normal conditions, but did not affect ATM activity.  
ATM binds to the A and C subunits, but this binding is dissociated after IR, partially in 
an ATM-dependent manner (55).  PP2A was able to dephosphorylate ATM S1981, but 
not as efficiently as Wip1, described below (163). 
 The PP2A interacting protein TIP binds directly to PP2A C and inhibits PP2A 
activity.  PP2A was found to oppose the ATM and ATR phosphorylation of a 32kD 
protein and TIP prevented this function of PP2A (115).  In X. laevis nucleoplasmic 
extracts, DSB inhibit replication by inhibiting the loading of Cdc45, RPA, and 
polymerase α onto DNA.  However, PP2A and caffeine, an inhibitor of ATM and ATR, 
was able to reverse the inhibition of replication and restore loading of the necessary 
factors (142). 
 Two different Wip1 mouse models have shown a role for Wip1 in negatively 
regulating ATM.  E1A+Ras expressing Wip1-null MEFs were seen to have an increase in 
ATM phosphorylation at S1987 (human S1981) and ATM activity under normal 
conditions as well as after IR.  Phosphorylation of p53 S18 (human S15), the ATM 
phosphorylation site, was increased slightly as well (163).  Splenocytes from Wip1+/- and 
Wip1-/- mice in an Eµ-myc background displayed an increase in ATM phosphorylation 
and p53 S18 phosphorylation (164).  Wip1+/- and Wip1-/- mice were more resistant to 
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tumor formation and this was dependent on ATM and p53 (164).  Wip1 was found to 
dephosphorylate ATM at S1981, S367 and S1893 in vitro (163, 164).   
 In human cells, the overexpression of Wip1 decreased ATM autophosphorylation 
and ATM-dependent CHK2 phosphorylation after IR.  The induction of Wip1 protein 
levels in control cells correlated with the decrease in phosphorylated ATM after IR.  
ATM phosphorylation also remained longer after IR in cells that had decreased Wip1.   
Wip1 could dephosphorylate ATM S1981 in vitro (163).  Another study, however, used a 
tetracycline-inducible Wip1 and showed that the expression of Wip1 after IR did not 
have an effect on S1981 phosphorylation (106).  This difference may be due to the 
different cell lines and conditions used.  
 
RPA 
 After treatment with and removal of HU, RPA32 is dephosphorylated at S21 and 
S33.  Inhibition of PP2A with OA or knockdown via siRNA results in persistence of RPA 
phosphorylation and foci.  An RPA mutant that could not be dephosphorylated resulted in 
reduced cell viability following UV or HU treatment and reduced DNA repair following 
replication stress (48).  This implicates PP2A in the recovery of the DDR. 
 
CHK1 
 CHK1 has been shown to be negatively regulated by multiple PSPs.  In S. pombe, 
the PP1 homologue Dis2 negatively regulates CHK1.  Cells lacking Dis2 have a 
prolonged G2 arrest following treatment with the double-strand break inducer MMS 
(methylmethane sulfonate) or the UV mimetic 4-NQO (4-nitroquinoline-N-oxide) but 
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DNA repair is not affected.  The overexpression of Dis2 caused a decrease in CHK1 
activation following UV (35).  CHK1 S345 could be dephosphorylated in vitro by Dis2 
or human PP1 (35, 106).   
 In human cells, the inhibition of PP2A induced CHK1 phosphorylation in the 
absence of DNA damage and also prevented CHK1 dephosphorylation after HU removal.  
The knockdown of PP2A increased CHK1 phosphorylation on S317 and S345 and in 
vitro, PP2A was able to directly dephosphorylate CHK1 (88).  In X. laevis egg extracts, 
the addition of PP2A C reversed CHK1 phosphorylation at S344 (human S345) after 
activation by DSB.  The inhibition of PP2A also enhanced CHK1 phosphorylation 
following activation by DSB (142). 
 Human CHK1 is also regulated by Wip1.  Wip1 could dephosphorylate CHK1 
primarily at S345 and slightly at S317 in vitro.  In vivo, the overexpression of Wip1 
resulted in the elimination of CHK1 phosphorylation at S345 and S317, a decrease of 
Cdc25C phosphorylation at S216, a decrease in Cdk1 phosphorylation at Y15, and a 
decrease in the S-phase and G2/M checkpoints, whereas the knockdown of Wip1 via 
siRNA caused the reverse effects.  Breast cancer cell lines with overexpression of Wip1 
(MCF-7, BT474, and MDAMB231) showed only a marginal increase in CHK1 S345 
phosphorylation after UV as compared to the control cells (HEK and U2OS) (106).  
Interestingly, Wip1-/- MEFs in a 129/sv-C57BL6 background showed a greater increase 
in phosphorylation at S345 in CHK1 after IR than wild-type MEFs whereas Wip1+/+ and 
Wip1-/- splenocytes expressing Eµ-myc did not show any difference in Chk1 S345 
phosphorylation, possibly indicating a cell type specific or DNA damage specific 
regulation of CHK1 via Wip1 (106, 164). 
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 In summary, CHK1 phosphorylation at S317 and S345 and CHK1 activity 
following DNA damage are regulated by PP1, PP2A, and Wip1.  This seems to play an 
important role in recovery from the DDR checkpoints. 
 
CHK2 
 Much of the work examining the negative regulation of CHK2 has been done 
using the S. cerevisiae CHK2 homologue Rad53.  The PP2C phosphatases Ptc2 and Ptc3 
as well as the type 2A phosphatase Pph3 have all been shown to negatively regulate 
Rad53 under different circumstances.  To study double-strand breaks in yeast, a system 
that induces the HO endonuclease to create a single double-strand break at a specific 
locus that cannot be repaired by homologous recombination was utilized (57).  A single 
break will cause a G2/M arrest and then adaptation to the checkpoint.  Cells lacking Ptc2 
and/or Ptc3 were defective in adaptation to an HO-induced G2/M arrest.  Ptc2 and Ptc3 
were required for recovery from the checkpoint as measured by Rad53 dephosphorylation 
and release from the G2/M checkpoint.  Ptc2 and Ptc3 bind to the FHA1 domain of Rad53 
and protein kinase CK2 phosphorylation of Ptc2 at T376 is necessary for this interaction 
(57, 87).  Mutation of this site prevented adaptation and recovery of the G2/M checkpoint 
(57).  Therefore, Ptc2- and Ptc3-mediated dephosphorylation of Rad53 results in recovery 
from the G2/M checkpoint. 
 Also in S. cerevisiae, deletion of the PP2A-like phosphatase Pph3 caused 
hypersensitivity to MMS.  Pph3-Psy2 binds to Rad53 and dephosphorylates it directly.  
The Pph3-Psy2 complex is necessary for the dephosphorylation of Rad53 during 
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recovery from the intra-S-phase checkpoint and it promotes the resumption of normal 
DNA synthesis following removal of MMS (131). 
 One study attempted to differentiate the roles of Pph3, Ptc2, and Ptc3 in 
negatively regulating Rad53.  Cells lacking Pph3 again showed hyperphosphorylation of 
Rad53, but Rad53 was still deactivated after MMS treatment.  Cells lacking Pph3, Ptc2, 
and Ptc3 have impaired Rad53 deactivation following MMS treatment, although Rad53 
deactivation from replication stress is only slightly delayed.  Pph3 is not required for 
Rad53 dephosphorylation and deactivation following replication stress.  Ptc2 and Ptc3 
were not required for Rad53 deactivation and dephosphorylation following genotoxic 
stress in S-phase via HU (184).  Thus, distinct phosphatases appear to be required for the 
dephosphorylation and deactivation of Rad53 following various DNA damages and the 
phosphatase required for recovery from replication stress has not yet been identified. 
 In humans, CHK2 was also found to be regulated by PP2A and Wip1.  Inhibition 
of PP2A using OA increased the phosphorylation of CHK2.  Although PP2A was also 
found to negatively regulate ATM, the effect on CHK2 phosphorylation is ATM-
independent (55).  Utilizing a yeast two-hybrid system, an in vitro binding assay, and co-
immunoprecipitation, CHK2 was found to bind to PP2A A, C, and many B' subunits.  
CHK2 was able to phosphorylate B'γ1 and B'γ3 in vitro and this increased PP2A activity 
in vitro.  The overexpression of B'γ3 resulted in a decrease in CHK2 phosphorylation 
after adriamycin treatment, which causes DNA adducts (40).  Following cisplatin 
treatment, PP2A containing a B subunit was found to bind to CHK2.  Inhibition of PP2A 
with OA or knockdown via siRNA caused an increase in CHK2 phosphorylation at T68.  
PP2A was found to dephosphorylate CHK2 in vitro as well (96).   
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   Wip1 and CHK2 bind in the nucleus and binding is dependent upon the CHK2 
SQ/TQ domain, kinase activity, and nuclear localization signal (NLS) and the Wip1 N-
terminal domain (50, 206).  Endogenous Wip1 and CHK2 can bind in MCF7 cells, which 
have a higher expression level of Wip1 and in A549 cells (50, 206).  Using GST-Wip1 in 
a GST pulldown assay with lysates of HCT15 cells stably expressing HA-CHK2, Wip1 
was seen to bind to CHK2 only after IR, suggesting that CHK2 phosphorylation is 
important for the interaction (136).  In vitro, Wip1 can dephosphorylate CHK2 at S19, 
S33/35, T68, T432, and S516 and this significantly reduces CHK2 kinase activity (50, 
136).  Overexpression of Wip1 inhibited CHK2 kinase activity in vitro, and in vivo, 
decreased T68 phosphorylation, caused a delay in CHK2 activation following IR, and 
caused a delay in G2/M arrest (50, 136).  Knockdown of Wip1 resulted in sustained 
CHK2 T68 phosphorylation and kinase activity following IR, as well as an increase in 
apoptosis (50).  In the acute promyelocytic leukemia (APL) cell line NB4, arsenic 
trioxide could induce CHK2 T68 phosphorylation through the inhibition of Wip1 (205).  
Finally, in stomach adenocarcinoma tumors, high Wip1 expression correlated with low 
CHK2 phosphorylation (51). 
 In yeast, Rad53 is negatively regulated by PP2A-like and PP2C-like 
phosphatases.  In humans PP2A and the PP2C phosphatase Wip1 have been shown to 
negatively regulate CHK2.  These phosphatases have been demonstrated to negatively 
regulate the activation of CHK2 as well as dephosphorylate it to allow for recovery from 
DDR checkpoints. 
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H2AX  
 PP1, PP2A and PP4 have been implicated in negatively regulating γ-H2AX.  In 
yeast, deletion of any of the PP4-like complex HTP-C genes (Pph3, Psy2, and Ybl046w) 
increases the amount of cellular γ-H2AX.  HTP-C can dephosphorylate γ-H2AX in vitro.  
Although Pph3 deficient cells had similar rates of DSB repair and loss of γ-H2AX foci as 
wild-type cells, even though H2AX remained phosphorylated, Rad9 (human 53BP1) and 
Rad53 (human CHK2) remained active longer and this correlated with maintenance of 
the G2/M checkpoint (76). 
 In human cells, the inhibition of PP1 partially inhibited the elimination of γ-
H2AX after DNA damage induced by IR (129).  The inhibition of PP2A or knockdown 
with siRNA increased the amount of γ-H2AX, increased the amount of foci-positive 
cells, increased the intensity of the foci, and increased the amount of time the foci were 
maintained following treatment with the topoisomerase I inhibitor camptothecin (CPT) 
(27).  Although PP1 has been shown to dephosphorylate γ-H2AX in nucleosomes in 
vitro, PP2A is at least 25 times more active toward γ-H2AX in monomeric form or when 
incorporated into nucleosomes (27, 129).  Indeed, PP2A C co-localizes with and binds to 
γ-H2AX after CPT treatment and the binding increases with increasing DNA damage 
(27).   
 Thus far, PP2A and PP4 have been implicated in negatively regulating γ-H2AX.  
In cells with both PP4C and PP2A C knocked-down, γ-H2AX levels were higher and 
sustained longer after CPT as compared to control cells, although the PP2A C 
knockdown had a greater effect.  PP2A C and PP4C had comparable abilities to 
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dephosphorylate γ-H2AX from mononuclosomes in vitro (28).  Both PP2A and PP4, but 
not PP1, can dephosphorylate γ-H2AX in vitro from acid extracted histones.  Knockdown 
of PP4C and PP2A C caused an increase in the total levels of γ-H2AX in untreated and 
irradiated cells (128). 
 Further examination of the specific roles of PP2A and PP4 in the regulation of γ-
H2AX has found distinct roles for each.  PP4C silenced cells, but not PP2A silenced 
cells, showed an increase in γ-H2AX even before DNA damage (28).  PP2A C silenced 
cells were slightly weakened in the ability to repair DSB induced by X-rays but PP4C 
silenced cells were not impaired in DNA repair.  Knockdown of PP4C caused a slower 
decrease in γ-H2AX foci after IR but PP2A knockdown did not affect foci.  PP4C 
primarily dephosphorylated γ-H2AX associated with chromatin rather than in the 
nucleoplasm, whereas PP2A did not.  PP4C depleted cells delayed entry into mitosis, but 
did not have any problems with the initiation of the G2/M checkpoint (128). 
 In summary, the dephosphorylation of γ-H2AX is mediated through PP2A and 
PP4.  This is necessary for the recovery from the DSB-induced checkpoint. 
 
P53 
 P53 is negatively regulated through direct dephosphorylation by PP1 and PP2A 
and through the regulation of its negative regulator, Mdm2.  The phosphorylation of p53 
at S37 is required for p53 transcriptional activity.  PP2A binds to p53 following IR and 
dephosphorylates S37 (36).  Inhibition of PP2A with OA or siRNA causes an increase in 
p53 phosphorylation at S15 and an increase in p53 activity (121). 
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 By inhibiting PP1 and PP2A with 100nM OA and comparing to the inhibition of 
only PP2A with 10nM OA, it was shown that PP1 inhibition induces apoptosis in rabbit 
lens epithelial cells.  This is accompanied by an induction of p53 and the p53 target Bax 
(89).  Inhibition of PP1, but not PP2A, with OA or calyculin A increased apoptosis in 
human lens epithelial cells in a p53-dependent manner.  Inhibition of PP1 only slightly 
increased p53 levels but dramatically increased p53 phosphorylation at S15 and S37 
which enhance regulation of p53 targets Bcl2 and Bax.  PP1 dephosphorylates p53 at S15 
and S37 in vitro and in vivo and this decreases its transcriptional activity and attenuates 
apoptosis (90). 
 Wip1 is induced in response to IR in a p53-dependent manner as a part of a 
negative feedback mechanism (26, 49).  Wip1-/- MEFs exhibit a slight increase in p53 
phosphorylation at S15 and an increase in the levels of p53 target p21 (26).  In an in vitro 
assay, Wip1 could dephosphorylate p53 on S15 but not S46.  After IR, Wip1-/- MEFs had 
an increase in phosphorylated S15.  An increase in the protein levels of Wip1 decreased 
p53 protein levels and S15 phosphorylation whereas knockdown of Wip1 with siRNA 
resulted in increased p53 protein levels and S15 phosphorylation.  In this system, Wip1 
did not have an effect on ATM or ATR after IR or UV, respectively, therefore the effect 
on p53 seems to be direct (106). 
 Wip1 plays an important role in the cell growth and cycle checkpoints in a p53-
dependent manner.  Overexpression of Wip1 led to a decrease in colony formation (49).  
Wip1-/- mice displayed a defect in T cell maturation due to sustained p53 activation (157).  
Wip1-/- MEFs have a more robust G1 arrest following IR, which may be due to increased 
activity of p53 (26).  Wip1 was required for recovery from arrest in G2 in a p53-
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dependent manner (99).  Overexpression of Wip1 decreased the S-phase and G2/M 
checkpoints whereas siRNA knockdown of Wip1 increased the intensity and length of the 
S-phase and G2/M checkpoints after UV and IR (106).  Interestingly, the Wip1 gene was 
found to be amplified in 11% of human breast tumors, most of which had wild-type p53 
(15).  These data collectively suggest that the negative regulation of p53 by Wip1 
contributes to tumorigenesis. 
 Not only is p53 regulated by multiple PSPs directly, but it is also regulated 
indirectly through the regulation of Mdm2.  Mdm2 was predicted to be a Wip1 substrate 
(203).  Indeed, Wip1, but not PP2A, dephosphorylates Mdm2 at S395, which is an ATM 
phosphorylation site (105, 114).  Wip1 dephosphorylation at S395 increases the stability 
of Mdm2 and increases the Mdm2-p53 interaction.  Wip1 inhibits Mdm2 auto-
ubiquitination thereby stabilizing the protein (105).  
 The induction of p53 causes an induction of cyclin G and increased binding 
between cyclin G and PP2A B'γ3 (134).  Cyclin G preferentially associates with B'γ3 in 
the active holoenzyme complex.  It appears to act as a recruitment factor to bring PP2A 
to Mdm2 so PP2A can dephosphorylate Mdm2 at S216 and S166.  This increases Mdm2 
binding to p53, thereby negatively regulating it (135).  Overexpression of PP2A B'γ3 and 
B'γ2 increases the levels of cyclin G1 protein.  Ectopic expression of B'γ3 counteracts the 
DNA damage-induced destabilization of cyclin G1 (92). 
 In conclusion, the multiple modes of regulation of p53 and its activation of 
negative feedback loops signifies the importance of keeping p53 tightly regulated after 
DNA damage.  PSPs play a role in regulating p53 through direct dephosphorylation via 
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PP1 and PP2A as well as enhancement of Mdm2 negative regulation of p53 through 
PP2A. 
 
DNA Damage Response Proteins Whose Activities are Enhanced 
 In contrast to the many instances of negative regulation of DDR proteins by PSPs, 
there are also specific cases in which certain phosphatases enhance the activity of 
proteins in the pathway (Figure 4).   
 
ATM 
 PP5 has been shown to play an important role in the activation of the DDR 
through ATM.  Cells with decreased PP5 protein or activity exhibited a decrease in ATM 
autophosphorylation at S1981, a decrease in ATM kinase activity, and a phenotype of 
RDS after DNA damage, which is consistent with the phenotype of cells lacking ATM 
activity (4).  PP5-deficient MEFs displayed a defect in the G2/M checkpoint after IR, a 
decrease in ATM activity, and less phosphorylation of ATM targets CHK2 and Nbs1 
after DNA damage (207).  In fact, PP5 was found to bind to ATM, and this binding was 
increased after treatment with NCS or IR (4). 
 Interestingly, ATM plays a role in activating PP1 and this is important for the 
G2/M checkpoint.  It has been shown that PP1 is activated following DNA damage 
caused by IR (59).  ATM phosphorylates the PP1 inhibitor I-2 at S43, causing 
dissociation of PP1 and I-2.  This phosphorylation is necessary for the dephosphorylation 
of PP1 at T320 (183).  These two actions cause an increase in PP1 activity (59, 183).  
PP1 then inhibits Aurora-B kinase activity resulting in a G2/M checkpoint (183). 
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ATR   
 HIV-1 Vpr (viral protein R) induces a G2 checkpoint through ATR and the 
phosphorylation of Cdk1 at Y15 (43, 65, 145, 149).  PP2A is necessary for this Vpr-
induced checkpoint.  Inhibition of PP2A with OA or knockdown of the PP2A A or C 
subunits resulted in a decrease in the amount of cells arrested at the Vpr-induced G2/M 
checkpoint, a decrease in Vpr-induced Cdk1 Y15 phosphorylation, and a decrease in 
phosphorylation of CHK1 S345 (43, 111).  This was only in a Vpr-induced fashion, as 
PP2A had no effect on pS345-CHK1 after UV or HU (91).  
 In addition to its role in activating ATM, PP5 was also shown to be important for 
the activation of ATR.  PP5 can bind to ATR after treatment with NCS, UV, and HU.  
PP5 was necessary for the phosphorylation of CHK1 at S345 and the knockdown of PP5 
inhibited the replication checkpoint after UV, inhibited the S-phase checkpoint after HU, 
and decreased RPA phosphorylation and foci formation (211). 
 
DNA-PK 
 PP1, PP2A, and PP6 have all been shown to positively influence DNA-PK 
activity.  When PP1 was added to DNA-PK complexes that were induced to 
autophosphorylate, the reduction in activity and disruption of the DNA-PK-DNA binding 
due to the autophosphorylation were reversed (120).  PP2A dephosphorylates DNA-PKcs 
as well as Ku70 and Ku80 leading to increased DNA-PK activity (39).  This opposes the 
autophosphorylation of DNA-PK that results in decreased activity of DNA-PK (20).  
CPT-induced DSB increased the association between PP2A and Ku proteins.  PP2A 
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dephosphorylation of DNA-PKcs and Ku increases the association between the DNA-PK 
proteins and this promotes DNA repair (193).   
 PP6 and DNA-PK form a complex in cells and this binding increases after IR.  IR 
causes a translocation of DNA-PK and PP6 from the cytoplasm to the nucleus and it 
appears that localization of the phosphatase is dependent on the kinase and vice versa.  
Knockdown of PP6 almost completely abolished the increase in DNA-PK activity after 
IR, caused a defect in DSB repair, and resulted in colongenic survival similar to DNA-PK 
knockdown cells, which means they have a higher sensitivity to IR (123). 
 
BRCA1 
 PP1 can dephosphorylate BRCA1 at the CHK2 site S988, the ATM site S1524, 
and the ATR site S1423 (101, 208).  The overexpression of PP1 can partially inhibit the 
hyperphosphorylation of BRCA1 after IR (101).  Since PP1 can dephosphorylate BRCA1 
at sites that have been shown to be important for BRCA1 function, it was intriguing to 
find that PP1 may actually act to enhance BRCA1 function.  PP1 specifically binds to 
BRCA1 amino acids 898-901 (KVTF) (197, 208).  Mutation of this site negatively 
affected HR and the localization of the HR factor Rad51 to the break site, which are 
functions of BRCA1 (208).  Interestingly, in human tissues, PP1 mRNA levels were 
significantly higher in normal tissue as compared to sporadic breast tumors (197).  This 
implicates PP1 in the activation of BRCA1. 
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P53 
 Although p53 is negatively regulated via multiple PSPs, its activity is also 
enhanced by two phosphatases.  PP2Cα overexpression increases p53 transcription 
activity.  The overexpression of PP2Cα inhibits cell proliferation, cell cycle progression, 
and colony formation and induces apoptosis.  These effects are partially p53-dependent 
(133). 
 P53 phosphorylation at T55 leads to p53 degradation (94).  PP2A containing the 
B'γ1 or B'γ3 subunit dephosphorylates T55 in response to DNA damage which leads to 
the inhibition of cell proliferation and transformation.  In addition, protein levels of B'γ 
subunits increase after IR (93). 
 In conclusion, recent literature has demonstrated that PSPs have important 
functions in both the activation of the DDR and its negative regulation.  Negative 
regulation can mean keeping the protein in an inactive state or inactivating it following 
the repair of the DNA to allow for recovery from the cell cycle checkpoint.   
 
Summary and Rationale 
 The DDR is extremely important for cells to prevent the propagation of mutations 
that can lead to cancer.  A highly sophisticated network of cell signaling machinery 
coordinates cell cycle checkpoints, DNA repair, senescence, and apoptosis.  CHK2 plays 
an integral role in the successful function of the DDR, especially in response to double-
strand breaks.   
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 PSPs are increasingly being discovered to influence the activities of DDR 
proteins, both in positive and negative ways.  We have decided to further examine the 
role of CHK2 in the DDR and its regulation through its interactions with other proteins.   
 We have identified the B'α subunit of PP2A as a CHK2 interacting protein and 
demonstrate that it negatively regulates CHK2 phosphorylation, activity, and protein 
stability.  This work provides a novel mechanism for CHK2 regulation and may be 
important for checkpoint recovery.  
40 
 
 
 
 
 
 
MATERIALS AND METHODS 
Cloning 
 CHEK2 was cloned into the pGBKT7 vector via PCR of a human mammary 
gland cDNA library (CLONTECH Laboratories).  PCR was used to generate B'α 
fragments containing amino acid residues 1-486 (full length), 1-195, 1-322, 176-322, 
176-486, 304-486, 44-322, 89-322, 133-322, 1-282, and 1-195 from the clone that was 
identified in the yeast-two hybrid screen to bind to CHK2.  These fragments were all 
cloned into the pACT2 vector and the full-length was cloned into pCMV2-FLAG.  PCR 
was also used to generate fragments of CHK2 containing amino acid residues 1-303, 1-
194, 1-107, 89-194, 143-390, 195-336, 217-543, and 304-543.   These were cloned into 
the pGBKT7 vector.  Full length CHK2 was subcloned into the pCMV-Tag3B vector.  
The D347A, S33/35A, and S33/35E mutant forms of CHK2 were constructed via site-
directed mutagenesis and cloned into the pCMV-Tag3B and pcDNA3 vectors.  
 
Yeast Two-Hybrid 
 The yeast-two hybrid was performed via the MATCHMAKER Two-Hybrid 
System 3 (CLONTECH Laboratories), briefly described here.  First, full length CHEK2 
in pGBKT7 was transformed into AH109 yeast and selection was made on SD -Trp 
media.  Next, the human mammary gland library (CLONTECH Laboratories) in the 
pACT2 vector was transformed into the same yeast and selection was made on SD -Leu -
Trp -Ade -His minimal media to verify binding between CHK2 and any prey from the 
41 
 
library.  For the deletion fragment analysis, the full length gene encoding B'α in pACT2 
was co-transformed with each CHEK2 fragment in pGBKT7 or full length CHEK2 in 
pGBKT7 was transformed with each B'α gene fragment in pACT2 into AH109 yeast and 
selection was made on minimal media. 
 
Cell Culture, Transfection, and Reagents 
 293T cells were grown in DMEM media (Sigma) supplemented with 7.5% Fetal 
Bovine Serum (SAFC), 1% Penicillin Streptomycin (Gibco), and 0.5% Amphotericin-B 
(Sigma).  HCT15 cells were grown in RMPI media (Gibco; Sigma) supplemented with 
10% Fetal Bovine Serum, 1% Penicillin Streptomycin, and 0.5% Amphotericin-B.  
HCT116 wild type (WT) and HCT116 CHK2-/- cells were a gift from Bert Vogelstein and 
they were maintained in McCoy's 5A media (Gibco) supplemented with 10% Fetal 
Bovine Serum, 1% Penicillin Streptomycin, and 0.5% Amphotericin-B.  293T cells were 
transfected using Fugene 6 (Roche) and the HCT15 and HCT116 CHK2-/- cells were 
transfected using Lipofectamine 2000 (Invitrogen).  When indicated, cells were treated 
with wortmannin, okadaic acid, hydroxyurea, mitomycin C, or doxorubicin (all from 
Sigma) at the indicated concentrations. 
 
 
Immunoprecipitations 
 For endogenous co-immunoprecipitations, 293T cells were lysed with RIPA 
buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA pH 8.0, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS) or NETN buffer (20 mM Tris pH 8.0, 150 mM NaCl, 1 
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mM EDTA, 0.5% NP-40, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5 mM Sodium 
Vanadate, 0.5 mM Sodium Molybdate) and incubated with an antibody to CHK2 and 
Protein A/G PLUS-Agarose (Santa Cruz) in modified RIPA buffer (made without sodium 
deoxycholate and SDS) or NETN.  Samples were eluted via boiling in sample buffer and 
analyzed by immunoblotting.  For co-immunoprecipitations with overexpressed proteins, 
293T cells were transfected with a pCEP-4HA plasmid containing B'α, B'β, B'δ, B'ε, or 
B'γ3 (obtained from Addgene; originally deposited by D. Virshup), a pCMV2-FLAG 
plasmid containing B'α, or co-transfected with pCMV2-FLAG-B'α and wild-type CHK2 
or a mutated CHK2 construct in pcDNA3.  For immunoprecipitations via the HA tag, 
cells were lysed with NETN buffer and incubated overnight with monoclonal anti-HA 
agarose conjugate (Clone HA-7; Sigma).  Samples were eluted via boiling in sample 
buffer and analyzed by immunoblotting.  For immunoprecipitations via the FLAG tag, 
lysates were incubated with anti-FLAG M2 Affinity Gel (Sigma).  Samples were eluted 
with 150 ng/µL 3X FLAG peptide (Sigma) and analyzed by immunoblotting. 
 
Immunoblotting 
 Cell lysis was performed with NETN buffer.  Samples were incubated on ice for 
15 min and then centrifuged for 20 min at 13,000 rpm at 4ºC.  Lysates were separated by 
SDS-PAGE gel and transferred to PVDF membranes.  Membranes were immunoblotted 
using the following antibodies: CHK2 (Clone 7; Upstate), CHK2 (NT; ProSci, Inc.), 
PP2A A (Clone H-300; Santa Cruz), PP2A C (Clone 1D6; Upstate), PP2A B' (Upstate), 
CHK1 (Clone G4; Santa Cruz), CHK2 phospho-serine 19 (Cell Signaling), CHK2 
phospho-serines 33/35 (Cell Signaling), CHK2 phospho-threonine 68 (Cell Signaling), 
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CHK1 phospho-serine 317 (Cell Signaling), Talin (Clone TA205; Upstate), PARP (BD 
PharMingen), H2AX (Upstate), FLAG (M2, peroxidase conjugate; Sigma), β-actin 
(Clone AC-74; Sigma), HA (Clone 3F10; Roche).  Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) or Amersham ECL Plus Western Blotting 
Detection Reagent (GE Healthcare) was used for detection. 
 
Kinase Activity Assay 
 293T cells, 293T cells transiently transfected with pCMV2-FLAG empty vector 
or one containing FLAG-B'α, or HCT15 cells transiently transfected with a pCMV-
Tag3B empty vector or one containing myc-tagged CHK2 WT, D347A, S33/35A, or 
S33/35E were irradiated with 20 Gy IR or mock treated.  Cells were lysed with NETN 
buffer and immunoprecipitated using an antibody to CHK2 or the c-Myc tag (Clone 
9E10; Santa Cruz) and Protein A/G PLUS-Agarose (Santa Cruz).  Immunoprecipitates 
were washed with NETN followed by kinase assay buffer (50 mM Tris-HCl pH7.5, 10 
mM MgCl2, 2 mM dithiothreitol, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5 mM 
sodium vanadate, 0.5 mM sodium molybdate).  Kinase reactions were carried out at 30ºC 
for 30 min in kinase assay buffer containing 25 µM ATP and 10 µCi [γ-32P]ATP with 
either 2 µg GST-B'α or 1 µg of GST-Cdc25C (amino acids 200-256) as a substrate using 
equivalent amounts of GST as a negative control.  Reactions were stopped by addition of 
sample buffer, boiled, and separated by SDS-PAGE gels which were then immunoblotted 
for CHK2 and autoradiographed.  The plasmid containing GST-Cdc25C (amino acids 
200-256) was a gift from Larry Karnitz (154). 
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Subcellular Fractionation 
 Cells were fractionated into cytoplasmic, nucleoplasmic, and chromatin fractions 
using a modified EMSA protocol (146).  Buffer A (20 mM Tris pH 7.4, 10% glycerol, 10 
mM KCl, 0.2% NP-40, 1 mM EDTA, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5 
mM Sodium Vanadate, 0.5 mM Sodium Molybdate, 0.6 mM β-mercaptoethanol) was 
added to cells, mixed by flicking, and left on ice for 15 min.  Samples were spun down 
for 2 min at 14,000 rpm at 4ºC and the supernatant was saved as the cytoplasmic fraction.  
The pellet was washed once with Buffer A, then Buffer B (20 mM Tris pH 7.4, 20% 
glycerol, 10 mM KCl, 400 mM NaCl, 1 mM EDTA, 1X protease inhibitors (Sigma), 1 
mM PMSF, 0.5 mM Sodium Vanadate, 0.5 mM Sodium Molybdate, 0.6 mM β-
mercaptoethanol) was added and mixed by pipeting.  Samples were incubated on a 
rocking platform at 4ºC for 20 min then centrifuged at 14,000 rpm for 15 min at 4ºC.  
The supernatant was saved as the nuclear fraction.  Acid extraction buffer (0.5 M HCl, 
10% glycerol, 100 mM β-mercaptoethanol) was added to the remaining pellet, vortexed, 
incubated for 2 min, and centrifuged at 14,000 rpm for 5 min.  Neutralization buffer (40 
mM Tris pH 7.4, protease inhibitors) was added and the samples were adjusted to a pH of 
7.4 and saved as the chromatin fraction.  Immunoblot analysis was performed. 
 
Phosphatase Activity Assay 
 Phosphatase activity was measured using the PP2A Immunoprecipitation 
Phosphatase Assay Kit (Upstate) following the manufacturer's instructions.  Briefly, cells 
were lysed with NETN buffer and immunoprecipitated with an antibody to PP2A C (for 
total PP2A activity) or FLAG (for activity of PP2A containing FLAG-B'α).  
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Immunoprecipitates were incubated with a phosphopeptide for 10 min at 30ºC and free 
phosphate was measured by addition of Malachite Green Detection Solution and the 
absorbance levels were read at 650 nm. 
 
Protein Stability 
 HCT15 cells were transiently transfected with a pcDNA3 plasmid containing 
CHK2 WT, S33/35A, or S33/35E.  24 h later, 100 µg/mL cycloheximide was added to all 
plates to inhibit new protein synthesis and the cells were mock-irradiated or irradiated 
with 20 Gy IR and collected every two hours.  The 0 h time point was mock-irradiated 
only.  Cells were lysed with NETN buffer and analyzed by immunoblotting.  
AlphaEaseFC software (Alpha Innotech) was used for densitometry analysis of the 
immunoblot bands.  This data was plotted on a graph and the best-fit line was generated 
to allow for comparison of the slopes of each line, which corresponds with the rate at 
which the protein was being degraded. 
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RESULTS 
CHK2 Binds to the B'α Subunit of PP2A 
 While much is known about the signaling networks that function in the DDR, not 
much is known about the negative regulation of the proteins involved in the absence of 
damage as well as during recovery from the checkpoint.  To this end, we decided to 
identify novel interacting partners of CHK2 using the yeast two-hybrid system, identify 
the binding domains, and verify the interaction in mammalian cells. 
 
CHK2 Interacts with the B'α Subunit of PP2A in Yeast. 
 In order to identify novel interacting proteins of CHK2, we utilized the yeast two-
hybrid system.  The full length CHEK2 gene was cloned into the pGBKT7 vector, which 
expresses proteins fused to the GAL4 DNA binding domain and allows growth on media 
lacking Tryptophan.  We used this construct to screen a human mammary gland cDNA 
library in the pACT2 vector, which expresses proteins fused to the GAL4 Activation 
domain and allows growth on media lacking Leucine.    When there is an interaction 
between the protein fused to the DNA binding domain and the protein fused to the 
activation domain, this results in the expression of genes which allow growth on media 
lacking Adenine and Histidine.  Therefore, interacting partners of CHK2 were isolated 
based on their ability, when co-expressed with wild-type CHK2, to allow yeast to grow 
on media lacking Adenine, Histidine, Leucine, and Tryptophan. 
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 In this screening, we identified two independent clones of the B'α regulatory 
subunit of PP2A (gene name: PPP2R5A).  As proof that our CHK2 construct was 
properly folded, we also identified two interacting proteins of CHK2 that have been 
previously described: KPNA2 and Mus81.  Karyopherin KPNA2 has been shown to bind 
to a NLS of CHK2 and this interaction is important for proper CHK2 localization in the 
nucleus (209).  Mus81, a damage tolerance protein, was shown to bind to the FHA 
domain of the S. pombe homologue of CHK2, Cds1, and appears to be important in the 
function of the DNA damage response cell cycle checkpoints in response to UV and 
replication stress (13). 
 To further investigate the interaction between B'α and CHK2, we mapped the B'α 
interacting domain in CHK2.  Multiple deletion constructs of CHEK2 were constructed 
via PCR and cloned into the pGBKT7 vector.  Each was co-transformed with the pACT2 
vector containing the full length B'α.  Binding was determined using the yeast-two hybrid 
system and was defined as growth of colonies on minimal media (-Ade, -His, -Leu, -Trp) 
as in the original yeast two-hybrid screening.  The minimal CHK2 fragment that bound to 
full length B'α was comprised of amino acid residues 1-107. This region contains the 
entire SQ/TQ region (Figure 5), where ATM phosphorylates CHK2 at S19, S33, S35 and 
T68, leading to the full activation of CHK2.   
 To determine the CHK2 binding region in B'α, multiple deletion constructs were 
constructed of B'α in pACT2 and each was co-expressed with full length CHK2 in 
pGBKT7. Binding was determined using the yeast-two hybrid system, again defined as 
growth in minimal media.  The minimal binding region in B'α was found to contain 
amino acid residues 89-322 (Figure 6).  Although this region spans almost half of the 
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protein, the crystal structure of the PP2A holoenzyme containing B'γ1, which is closely 
related to B'α, reveals unique features of this enzyme (25, 201).  B'γ1 contains eighteen α 
helices which form eight HEAT-like repeats and the interaction to the A and C subunits 
is mediated by many residues scattered throughout the B'γ1 protein (201), as noted in 
Figure 6.  Therefore, it is probable that there are select residues within this span of amino 
acid residues 89-322 that are particularly important for the interaction to CHK2.  
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Figure 5.  B'α binds to CHK2 amino acids 1-107.  The full length CHK2 protein is 
shown with phosphorylation sites and domains highlighted.  The SQ/TQ domain is 
displayed in light gray, the FHA domain in dark gray, and the kinase domain in black.  
Using the yeast two-hybrid system, deletion mutants of CHK2 were co-transformed into 
yeast with full-length B'α.   
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Figure 6.  CHK2 binds to B'α amino acids 89-322.  Full length B'α is shown with the 
residues responsible for binding to the PP2A A subunit in light gray and the C subunit in 
dark gray (201).  Using the yeast two-hybrid system, deletion mutants of B'α were co-
transformed with full-length CHK2.    
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CHK2 and B'α Bind in Mammalian Cells 
 We next wanted to verify the binding of B'α and CHK2 in a mammalian system.  
293T cells were transiently transfected to express FLAG-B'α.  Whole cell extracts were 
immunoprecipitated using a FLAG antibody and eluted using an excess of FLAG 
peptide.  This prevents the appearance of the heavy and light chains of the 
immunoglobulin on the Western blot and significantly reduces background.  The 
immunoprecipitate was immunoblotted for endogenous CHK2, demonstrating that B'α 
and CHK2 interact in vivo (Figure 7).    Immunoblotting also detected the endogenous 
PP2A A and C subunits, indicating that FLAG-B’α is able to function as a member of the 
potentially active heterotrimeric PP2A complex. 
 To ensure that the binding of CHK2 with B'α occurs without overexpression of 
the B'α protein, immunoprecipitation of the endogenous proteins was utilized.  Whole 
cell lysates of 293T cells were immunoprecipitated using a CHK2 antibody and were 
then analyzed via Western blot using an antibody to B'α.  As shown in Figure 8, B'α was 
able to bind to CHK2, verifying that this interaction occurs with the endogenous levels of 
both proteins. 
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Figure 7.  CHK2 binds to FLAG-B'α in mammalian cells.  Whole cell lysates of 293T 
cells expressing FLAG-B'α were immunoprecipitated (IP) using the FLAG antibody and 
immunoblotted (IB) for the indicated proteins.  Cell lysates that were not expressing 
FLAG-B'α were used as a negative control. 
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Figure 8.  Endogenous CHK2 and endogenous B'α bind in mammalian cells.  Whole 
cell lysates of 293T cells were immunoprecipitated using an antibody to CHK2 and 
immunoblotted for B'α.  Normal mouse IgG was used as a negative control for the 
immunoprecipitation.  
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Binding Between CHK2 and PP2A is Modulated by DNA Damage 
 It is well characterized that CHK2 is activated upon the induction of DNA 
damage and this involves the phosphorylation of CHK2 at multiple sites, including the 
region that binds to B'α.  Therefore, we determined whether the binding between CHK2 
and B'α is modified under these conditions.  We also determined the extent to which 
CHK2 could bind other members of the B' family and the PP2A C catalytic subunit. 
 
B'α and CHK2 Dissociate upon IR-Induced DNA Damage. 
 Since CHK2 is activated upon DNA damage, we examined the binding between 
CHK2 and B'α for any changes upon the induction of DNA DSB by exposing cells to IR.  
Whole cell extracts of 293T cells transiently expressing FLAG-B'α were 
immunoprecipitated using a FLAG antibody and immunoblotted for endogenous CHK2, 
PP2A A and PP2A C (Figure 9).  Interestingly, when cells were exposed to 20 Gy IR and 
incubated for 1 h, this markedly reduced the binding of CHK2 to B'α without affecting 
the binding of B'α to the PP2A A and C subunits.  
 Phosphorylation of CHK2 serine 33 and 35 is recognized by the same antibody 
and therefore we will refer to them as S33/35. Immunoblotting of the lysate input verifies 
that IR causes phosphorylation of CHK2 at S19, S33/35, and T68 as previously described 
(3, 16, 113, 119), verifying the activation of CHK2 after IR (Figure 9). 
 To ensure that the dissociation seen between CHK2 and B'α in the previous 
experiment was not an artifact of the antibody that was used, we repeated the experiment 
but immunoblotted with a different CHK2 antibody from another company.  Again, 
CHK2 was seen to bind to B'α under normal conditions and after exposure to IR, CHK2 
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and B'α were dissociated (Figure 10).  This confirms that CHK2 and B'α are dissociated 
after IR and this is not due to specific reagents that were used.   
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Figure 9.  Binding between CHK2 and B'α is disrupted after DNA damage.  293T 
cells transiently expressing FLAG-B'α or empty vector (FLAG) were irradiated with 20 
Gy and incubated for 1 h.  Whole cell lysates were immunoprecipitated using a FLAG 
antibody and immunoblotted for the indicated proteins.  The CHK2 antibody used is anti-
CHK2 (clone 7) from Upstate Cell Signaling Solutions. 
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Figure 10.  Dissociation of CHK2 and B'α is verified using another CHK2 antibody.  
293T cells transiently expressing FLAG-B'α were irradiated with 20 Gy and incubated 
for 1 h.  Whole cell lysates were immunoprecipitated using a FLAG antibody and 
immunoblotted for the indicated proteins.  The CHK2 antibody used is anti-CHK2 (NT), 
from Pro Sci, Incorporated. 
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CHK2 Binds to Many PP2A Subunits. 
 We have determined that CHK2 binds to one member of the PP2A B' family, 
namely B'α.  The B' family of regulatory subunits is comprised of at least nine members 
encoded from five genes. To determine the specificity of CHK2 for additional B' 
proteins, HA-tagged B'α, B'β, B'δ, B'ε, and B'γ3 proteins were transiently expressed in 
293T cells.  Whole cell lysates were immunoprecipitated via an antibody to the HA tag.  
Endogenous CHK2 was efficiently immunoprecipitated by all of the B’ proteins tested 
(Figure 11), in agreement with a previous study that demonstrated CHK2's ability to bind 
to many B' proteins using an in vitro binding assay (40).  In our study, CHK2 had the 
strongest interaction to B'γ3 and the weakest to B'β, with binding to B'α, B'δ, and B'ε 
residing within this range.  Additionally, the CHK2-B' complexes were dissociated after 
the cells were exposed to IR.  It should be noted that the ability of the B'β protein to bind 
to the PP2A A and C subunits was compromised compared to the other B' proteins, 
suggesting there may be a problem with the conformation of this overexpressed B'β.   
 In order to determine whether CHK2 can bind to an active PP2A complex, we 
immunoprecipitated CHK2 from the whole cell lysates of 293T cells and immunoblotted 
for the PP2A C catalytic subunit (Figure 12).  Indeed, endogenous CHK2 was able to 
bind to endogenous PP2A C, suggesting that CHK2 can associate with an active PP2A 
complex through one of the B' regulatory subunits.  After the cells were exposed to IR to 
induce DNA damage, the binding between CHK2 and PP2A C is severely diminished, as 
was seen with the B' subunits. 
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Figure 11.  CHK2 binds to many PP2A B' subunits and they are dissociated after 
IR.  293T cells transiently transfected with HA-tagged B'α, B'β, B'δ, B'ε or B'γ3 were 
irradiated with 20 Gy and incubated for 1 h.  Whole cell lysates were immunoprecipitated 
with the HA antibody and immunoblotted for the indicated proteins.  CHK2 was able to 
bind to all B' proteins tested and all were at least partially dissociated by exposure to IR. 
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Figure 12.  Endogenous PP2A C and CHK2 can bind and they are dissociated after 
IR.  293T cells were irradiated with 20 Gy and incubated for 1 h.  Whole cell lysates 
were immunoprecipitated with an antibody to CHK2 and immunoblotted for PP2A C.   
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B'α and CHK2 are Dissociated After DNA Damage Caused by IR and Doxorubicin, but 
not B'α and CHK1  
 CHK2 can be activated by other types of DNA damage in addition to DSB caused 
by IR.  Therefore, other DNA damaging agents were also tested for any effects on the 
binding between CHK2 and B'α.  293T cells transiently expressing FLAG-B'α were 
exposed to IR, UV, HU, mitomycin C (MMC), or doxorubicin (Dox).  FLAG-B'α was 
immunoprecipitated and immunoblotted for endogenous CHK2, PP2A A and PP2A C.  
Interestingly, treatment with UV, HU, or MMC did not have any effect on the ability of 
CHK2 to bind to FLAG-B'α (Figure 13).  However, treatment with Dox did decrease the 
binding between the two proteins, but not to the extent that IR did.  By examining the 
phosphorylation of CHK2 in the lysate input via immunoblotting, it can be seen that the 
pattern of CHK2 phosphorylation was different after each treatment.  After IR and Dox, 
S19, S33/35, and T68 were all phosphorylated; after UV and MMC, T68 was primarily 
phosphorylated and S19 was weakly phosphorylated; and after HU, S19 and T68 were 
phosphorylated.  The dissociation between CHK2 and B'α occurs after IR and Dox: the 
only conditions that resulted in S33/35 phosphorylation at the time points studied. 
 Since CHK1 is also phosphorylated and activated in response to DNA damage in 
a similar manner to CHK2, we also tested whether CHK1 could bind to PP2A B'α and 
whether this binding was disrupted by DNA damage (Figure 13).  Interestingly, CHK1 
was able to bind to B'α, but this binding was not disrupted by treatment with IR, UV, 
HU, MMC, or Dox.  CHK1 was highly phosphorylated at S317 after IR, UV, and HU, 
which is in agreement with previous studies (53, 213).  This demonstrates that the 
modulation of the interaction by DNA damage is specific to the CHK2-B'α complex. 
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Figure 13.  Dissociation of CHK2 and B'α is caused by DNA damage induced by IR 
and doxorubicin.  293T cells transiently transfected with FLAG-B'α were exposed to 
either 20 Gy IR and incubated for 1 h, 50 J/m2 UV and incubated for 2 h, 2 mM 
hydroxyurea (HU) for 24 h, 0.5 µg/mL mitomycin C (MMC) for 24 h, or 1 mM 
doxorubicin (DOX) for 2 h.  Whole cell lysates were immunoprecipitated using the 
FLAG antibody and immunoblotted for the indicated proteins.   
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Analysis of the IR-Induced Dissociation of CHK2 and B'α 
 The previous experiments have demonstrated that CHK2 can bind to many B' 
family members as well as the C subunit and they are dissociated after specific types of 
DNA damage.  Since the dissociation of CHK2 and B'α occurs the most after treatment 
with IR, we decided to further characterize this dissociation by examining any dose 
dependence, the timing of dissociation, and whether they could re-associate at later points 
in time.  We also examined the role of phosphorylation in the binding and dissociation of 
CHK2 and B'α since the dissociation correlated with the phosphorylation of CHK2 at 
certain sites. 
  
Dissociation is an Early Event and Occurs in a Dose-Dependent Manner 
 Since we have observed that IR causes the most dissociation of B'α and CHK2 of 
all of the DNA damaging agents that we studied, we next ascertained which doses of IR 
provide maximal dissociation.  293T cells transiently expressing FLAG-B'α were 
exposed to 2, 5, 10, 20, or 50 Gy, and FLAG-B'α was immunoprecipitated and 
immunoblotted (Figure 14).  Maximal dissociation of endogenous CHK2 and B'α 
reached a peak after exposure to 10 Gy IR.  By examining the phosphorylation of CHK2 
in the lysate input, it can be seen that S19 phosphorylation increased with the increasing 
doses of IR.  T68 phosphorylation was maximal after 2 and 5 Gy, and then decreased 
with the increasing IR doses.  However, we observed the phosphorylation of S33/35 to be 
maximal after 10 Gy of IR.  This corresponds to the IR dose that induces maximal 
dissociation between CHK2 and B'α. 
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 In order to determine the precise timing of B'α and CHK2 dissociation after IR,  
293T cells transiently expressing FLAG-B'α were irradiated with 20 Gy IR and collected 
every half an hour from 0.5 h to 2.5 hours following IR.  FLAG-B'α was 
immunoprecipitated and it was found that CHK2 binding was minimal 0.5 h after IR, and 
the binding was slightly restored over the remainder of the time course (Figure 15).  
Significantly, the dissociation at 0.5 h correlated with maximal phosphorylation of CHK2 
at S33/35, but did not correlate with phosphorylation of S19 or T68. 
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Figure 14.  Dissociation of CHK2 and B'α occurs in a dose-dependent manner.  
293T cells were transiently transfected with FLAG-B'α and irradiated with 2, 5, 10, 20, 
or 50 Gy and incubated for 1 h.  Whole cell lysates were immunoprecipitated with the 
FLAG antibody and immunoblotted for the indicated proteins.   
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Figure 15.  Dissociation of CHK2 and B'α is an early event after IR.  293T cells were 
transiently transfected with FLAG-B'α and irradiated with 20 Gy and incubated for 0.5, 
1.0, 1.5, 2.0, or 2.5 h.  Whole cell lysates were immunoprecipitated with the FLAG 
antibody and immunoblotted for the indicated proteins. 
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Re-Association of CHK2 and B'α does Not Correlate With Resolution of DNA Damage 
 CHK2 plays an important role in activating cell cycle checkpoints after DNA 
damage (8).  Since we have established that PP2A B'α and CHK2 dissociate after IR, we 
investigated whether re-association at a later time was correlated to the resolution of 
DNA damage. We used two different doses of IR for comparison.  First, we exposed cells 
to a sub-lethal dose of 6 Gy, the lowest dose after which we could detect a significant 
dissociation between CHK2 and B'α and which would also allow for recovery.  We also 
exposed the cells to 50 Gy, which is considered lethal.  293T cells expressing FLAG-B'α 
were collected 1 h, 4 h, 8 h, and 12 h after exposure to both doses of IR (Figure 16 and 
Figure 17).  Interestingly, the kinetics of dissociation after 50 Gy were similar to that 
after 6 Gy.  CHK2 was dissociated from B'α after 1 h and began to re-associate 
approximately 4 h after IR with a subsequent increase through the remaining time points.  
After both doses, the phosphorylation of S19, S33/35, and T68 followed similar patterns.  
S33/35 had maximal phosphorylation after 1 h, again correlating with the most 
dissociation between CHK2 and B'α.  There does seem to be some difference in CHK2 
phosphorylation between the two doses, since after 6 Gy IR, the CHK2 that was bound to 
B'α after 4-12 h existed as a doublet, suggesting the existence of hyper and 
hypophosphorylated forms (Figure 16). 
 In order to assess how dissociation and re-association correlated with the 
resolution of DNA damage, we determined the levels of histone H2AX phosphorylated at 
S139, also known as γ-H2AX, which is a well characterized marker of DSB (148).  Thus, 
higher levels of γ-H2AX denote the presence of DSB.  When the breaks are repaired, γ-
H2AX levels return to levels found before DNA damage (in some cases it can no longer 
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be detected by Western blot or immunofluorescence).  In our experiments, after 6 Gy IR, 
the maximal amount of γ-H2AX appeared after 4 h, returning to pre-damage levels by 12 
h (Figure 16).  On the other hand, after 50 Gy IR, maximal levels of γ-H2AX were 
detected after 1 h and did not decline throughout the remainder of the time points (Figure 
17).  Since B'α and CHK2 were shown to re-associate throughout the time course, and 
DNA DSB were present during these times as show by the presence of γ-H2AX, the re-
association does not correlate with the resolution of the DSB. 
 In summary, dissociation of CHK2 and B'α is induced in a dose-dependent 
manner and is an early event after IR.  CHK2 and B'α re-association after DNA damage 
does not require resolution of the DNA damage. Moreover, dissociation and re-
association correlate with phosphorylation of S33/35 of CHK2.   
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Figure 16.  CHK2 and B'α are able to re-associate hours after 6 Gy IR.  293T cells 
were transiently transfected with FLAG-B'α and irradiated with 6 Gy and incubated for 
1, 4, 8, or 12 h.  Whole cell lysates were immunoprecipitated with the FLAG antibody 
and immunoblotted for the indicated proteins. 
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Figure 17.  CHK2 and B'α are able to re-associate hours after 50 Gy IR.  293T cells 
were transiently transfected with FLAG-B'α and irradiated with 50 Gy and incubated for 
1, 4, 8, or 12 h.  Whole cell lysates were immunoprecipitated with the FLAG antibody 
and immunoblotted for the indicated proteins. 
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The Activity of ATM, but not PP2A, is Necessary for the Dissociation of CHK2 and B'α. 
 We next investigated the importance of PP2A activity on the binding and 
dissociation of CHK2 and B'α.  OA is a phosphatase inhibitor that, when used at 0.5 µM, 
blocks the PP2A catalytic subunit's activity without affecting PP1 (55).  293T cells 
transiently expressing FLAG-B'α were treated with OA prior to IR exposure.  FLAG-B'α 
was immunoprecipitated using an antibody to the FLAG tag and immunoblot analysis 
was performed (Figure 18).  In the mock treated cells, CHK2 was able to bind to FLAG-
B'α, and this binding was unaffected by OA treatment alone.   After IR, CHK2 and B'α 
dissociated and the presence of OA did not affect the dissociation.  The inhibition of 
PP2A by OA also had no effect on the ability of FLAG-B'α to bind to the PP2A A and C 
subunits, indicating that it can still form the holoenzyme complex.  Therefore, PP2A 
activity is not required for B'α binding to, or dissociation from, CHK2. 
 As we have seen thus far, the most pronounced dissociation between CHK2 and 
B'α occurs when CHK2 is phosphorylated on S33/35, which are phosphorylated in an 
ATM-dependent manner (16, 79, 124).  ATM belongs to the PIKK family along with 
ATR and DNA-PK.  To determine whether the CHK2-B'α dissociation is a PIKK-
dependent event as is the phosphorylation of CHK2 S33/35, the PIKK inhibitor 
wortmannin was utilized at a concentration that inhibits ATM and DNA-PK, but not ATR 
activity in vivo (155).  293T cells transiently expressing FLAG-B'α were incubated with 
wortmannin prior to exposure to IR.  FLAG-B'α was immunoprecipitated using a FLAG 
antibody and immunoblot analysis was performed (Figure 19).  Pre-incubation with 
wortmannin prevented the dissociation of CHK2 from FLAG-B'α after IR.  This 
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treatment also inhibited the phosphorylation of S19 and S33/35, indicating that the 
phosphorylation of CHK2 is required for the dissociation of CHK2 and B'α. 
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Figure 18.  PP2A phosphatase activity is not required for CHK2 binding to or 
dissociating from B'α.  293T cells were transiently transfected with FLAG-B'α, treated 
with 0.5 µM OA for 1 h and then irradiated with 20 Gy IR and incubated for 1 h.  Whole 
cell lysates were immunoprecipitated with the FLAG antibody and immunoblotted for the 
indicated proteins. 
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Figure 19.  Inhibition of ATM and DNA-PK kinase activity prevents the IR-induced 
dissociation of B'α and CHK2.  293T cells were transiently transfected with FLAG-B'α, 
treated with 20 µM wortmannin for 1 h then irradiated with 10 Gy IR and incubated for 1 
h.  Whole cell lysates were immunoprecipitated with the FLAG antibody and 
immunoblotted for the indicated proteins. 
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Mutation of CHK2 Serines 33 and 35 Affects Binding to B'α 
 To further investigate the importance of the phosphorylation of CHK2 S33/35 on 
the binding and dissociation between CHK2 and B'α, we made two CHK2 mutants.  The 
substituted alanines for serines 33 and 35 to prevent phosphorylation (S33/35A) and the 
substituted glutamic acids to mimic phosphorylation (S33/35E).  Wild-type CHK2 
(CHK2 WT), S33/35A and S33/35E were co-transfected along with FLAG-B'α into 
HCT116 CHK2-/- cells, which were then mock-irradiated or irradiated with 20 Gy.  
FLAG-B'α was immunoprecipitated and immunoblot analysis was performed (Figure 
20).  In mock treated cells, we saw an increase in S33/35A binding to B'α and a decrease 
in S33/35E binding as compared to CHK2 WT.  Alternatively, after irradiation, CHK2 
WT and S33/35A bound at the same levels as mock treated CHK2 WT, however, 
S33/35E binding is completely abrogated.  
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Figure 20.  Mutation of CHK2 serines 33 and 35 affects binding to B'α.  HCT116 
CHK2-/- cells were transfected with FLAG-B'α and either wild-type CHK2 or the 
S33/35A or S33/35E mutants.  Whole cell lysates were immunoprecipitated with the 
FLAG antibody and immunoblotted for CHK2. 
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Analysis of the Effects of CHK2 on PP2A 
 Thus far, we have documented the binding between CHK2 and many PP2A 
subunits.  This is an interesting case in which a kinase and a phosphatase bind under 
certain circumstances.  As described above in detail, CHK2 phosphorylates a number of 
substrates which can positively and negatively regulate them.  PSPs play important roles 
in both positively and negatively regulating DDR proteins as well.  Therefore, it is 
possible that CHK2 kinase activity has an effect on PP2A activity, and vice versa.  In this 
next section, we will investigate whether PP2A B'α can be used as a substrate by CHK2 
and the extent to which CHK2 or DNA damage could affect PP2A localization or 
activity. 
 
CHK2 can Phosphorylate B'α in vitro. 
 Since CHK2 is a kinase that is activated after irradiation, we determined whether 
B'α could be used as a substrate for CHK2 in an in vitro kinase assay.  293T cells were 
irradiated to activate CHK2 which was then immunoprecipitated and incubated in a 
kinase reaction with GST-B'α (Figure 21).  Indeed, phosphorylated B'α was detected, 
indicating that in an in vitro system, CHK2 can phosphorylate B'α. 
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Figure 21.  CHK2 can phosphorylate B'α in vitro.  Whole cell lysates from irradiated 
293T cells were immunoprecipitated using an antibody to CHK2.  CHK2 kinase activity 
towards GST-B'α was measured using an in vitro kinase reaction. 
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PP2A Localization is Not Influenced by IR 
 Since CHK2 was able to phosphorylate B'α in vitro, we next determined if this 
had an effect on PP2A localization.  293T cells transiently expressing FLAG-B'α were 
mock-irradiated or irradiated with 20 Gy, separated into the cytoplasmic, nucleoplasmic 
and chromatin fractions, and subjected to immunoblot analysis (Figure 22).  CHK2 was 
located in the cytoplasm and nucleoplasm.  The slower migrating form of CHK2 after IR 
is indicative of its hyperphosphorylated active status.  The PP2A A and C subunits were 
also found in the cytoplasm and nucleoplasm, whereas FLAG-B'α was located in all three 
cellular compartments.  The localization in the chromatin fraction may be an effect of its 
overexpression, as the endogenous A and C subunits could not be detected.  Exposure of 
the cells to IR did not change the localization of any proteins examined, indicating that 
PP2A localization is not affected by DNA DSB caused by IR. 
 CHK2 was also found to bind to other B' family members in addition to B'α.  
Therefore, using an antibody that recognizes many B' proteins, we also examined the 
subcellular localization of the endogenous B' family.  As seen in Figure 23, there are 
endogenous B' proteins that are located in the cytoplasm and nucleoplasm, and the 
localization of each protein is not affected by exposure of the cells to IR. 
  
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  B'α localization is not changed by IR.  293T cells transiently expressing 
FLAG-B'α were mock-irradiated or irradiated with 20 Gy and incubated for 1 h.  Using a 
subcellular fractionation method, cells were separated into the cytoplasmic, 
nucleoplasmic, and chromatin fractions, and immunoblot analysis for the indicated 
proteins was performed.  Talin was used as a marker for the cytoplasm, PARP for the 
nucleoplasm, and H2AX for the chromatin.   
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Figure 23.  Localization of endogenous PP2A proteins do not change after IR.  293T 
cells were mock-irradiated or irradiated with 20 Gy and incubated for 1 h.  Using a 
subcellular fractionation method, cells were separated into the cytoplasmic, 
nucleoplasmic, and chromatin fractions, and immunoblot analysis for the indicated 
proteins was performed.  Talin was used as a marker for the cytoplasm, PARP for the 
nucleoplasm, and H2AX for the chromatin. 
82 
 
PP2A Activity is Unaffected by IR and is Not Influenced by CHK2 
 If CHK2 is indeed able to phosphorylate B'α in vivo, it may have an effect on 
PP2A activity.  We first examined the total PP2A activity in the cell.  The C subunit is 
responsible for all of the PP2A catalytic activity in the cell, regardless of which 
regulatory subunit is bound to the complex.  Therefore, 293T cells were either exposed to 
IR or mock treated and immunoprecipitated using an antibody to the C subunit to assess 
total PP2A activity.  Phosphatase activity of the immunoprecipitates was measured using 
an in vitro phosphatase assay (Figure 24).  The levels of PP2A activity were not changed 
by exposure to IR. 
 Next, the activity of the PP2A complexes specifically containing FLAG-B'α was 
determined.  293T cells transiently expressing FLAG-B'α were either exposed to IR or 
mock treated and immunoprecipitated using a FLAG antibody to measure only the 
activity of PP2A complexes containing B'α.  Phosphatase activity was measured using an 
in vitro phosphatase assay and was unaffected by exposure to IR (Figure 25).  Since the 
assay measures activity against a small peptide, this may not accurately reflect changes in 
phosphatase activity toward specific substrates, however, it is a measure of the total 
activity of PP2A containing the B'α subunit. 
 In order to determine whether CHK2 has an effect on PP2A activity, the HCT116 
wild-type (WT) cells and the isogenic HCT116 CHK2-/- cell lines were utilized.  Both 
cell lines were either exposed to IR or mock treated and immunoprecipitated using an 
antibody for the PP2A C subunit to measure total PP2A activity (Figure 26).  The in 
vitro phosphatase assay revealed no difference in PP2A activity in the mock treated or 
irradiated samples in either cell line.  Also, there was no difference observed between the 
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HCT116 WT or CHK2-/- cell lines, suggesting that CHK2 has no effect on PP2A activity 
under these conditions.  Taken together, this data indicates that PP2A activity is not 
affected by IR exposure or by CHK2. 
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Figure 24.  Total PP2A phosphatase activity does not change after IR.  293T cells 
were irradiated with 20 Gy or mock treated and incubated for 1 h.  Whole cell extracts 
were immunoprecipitated with an antibody to the PP2A C subunit.  Phosphatase activity 
of the immunoprecipitates was determined using an in vitro phosphatase assay.  The 
activity of the mock sample was defined as 100%.   
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Figure 25.  Phosphatase activity of PP2A containing B'α does not change after IR.  
293T cells transiently transfected with FLAG-B'α were irradiated with 20 Gy or mock 
treated and incubated for 1 h.  Whole cell extracts were immunoprecipitated using the 
FLAG tag.  Phosphatase activity was determined and the activity of the mock treated 
sample expressing FLAG-B'α was defined as 100%. 
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Figure 26.  Total PP2A activity does not differ in HCT116 wild-type and CHK2-/- 
cells.  HCT116 wild-type and HCT116 CHK2-/- cells were irradiated with 20 Gy and 
incubated for 1 h.  Whole cell extracts were immunoprecipitated using an antibody to the 
PP2A C subunit.  Phosphatase activity was determined and the mock sample from the 
HCT116 wild-type cells was defined as 100%. 
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Analysis of the Effects of PP2A on CHK2 
 We have shown that CHK2 does not seem to have any effect on PP2A activity or 
localization, even though in vitro CHK2 can use B'α as a substrate.  We next wanted to 
determine the extent to which PP2A can affect CHK2 phosphorylation, activity, and 
protein stability. 
 
Changes in CHK2 Phosphorylation due to IR 
 In order to determine the extent to which PP2A has an effect on the 
phosphorylation of CHK2, the PP2A inhibitor OA was utilized.  293T cells were treated 
with OA in the presence and absence of irradiation, and the amount of phosphorylation of 
CHK2 at specific sites was measured via immunoblotting (Figure 27).  Pre-treatment 
with OA increased the phosphorylation of CHK2 after IR, primarily at S19, although 
there were also slight increases in the phosphorylation of S33/35 and T68, demonstrating 
that PP2A can dephosphorylate CHK2 at multiple sites. 
 Since we have shown that mutation of S33/35 can influence the binding between 
B'α and CHK2, this led us to investigate any effect phosphorylation at these sites has on 
CHK2 function.  Therefore, we examined the ability of the S33/35A and S33/35E 
mutants to be phosphorylated at other CHK2 sites.  HCT15 cells (which lack functional 
CHK2) transiently expressing myc-tagged CHK2 wild-type (WT), kinase dead (D347A), 
S33/35A, or S33/35E were either exposed to IR or mock treated.  The phosphorylation 
status of each CHK2 protein was determined via immunoblotting (Figure 28).  In the 
mock treated samples, CHK2 WT and S33/35A showed a very faint phosphorylation of 
S19.  However, S33/35E displayed a much stronger phosphorylation, even in the absence 
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of DNA damage.  After exposure to IR, CHK2 WT was phosphorylated on S19, with 
levels comparable to the mock treated S33/35E.  The phosphorylation of S33/35A at S19 
was slightly compromised.  T68 phosphorylation was slightly higher in the S33/35A and 
S33/35E in both conditions as compared to CHK2 WT.  Therefore, the S33/35 mutations 
primarily affect S19 phosphorylation, the same site that was affected most by PP2A 
inhibition. 
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Figure 27.  Inhibition of PP2A activity increases CHK2 phosphorylation.  293T cells 
were incubated with 0.5 µM OA for 1 h then irradiated with 20 Gy and incubated for 1 h.  
Whole cell extracts were examined for phosphorylation levels of CHK2 via immunoblot.   
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Figure 28.  Mutation of CHK2 serines 33 and 35 affects CHK2 phosphorylation at 
other sites.  HCT15 cells transiently transfected with pCMV-Tag3B empty vector 
(vector) or myc-tagged CHK2 WT, D347A, S33/35A or S33/35E were exposed to 20 Gy 
IR or mock treated and incubated for 1 h.  Whole cell extracts were examined for CHK2 
phosphorylation via immunoblot.   
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Changes in CHK2 Kinase Activity after IR 
 To directly measure the affect of PP2A on CHK2 activity, we transfected 293T 
cells with FLAG-B'α and measured CHK2 kinase activity using an in vitro kinase assay 
with GST-Cdc25C (amino acid residues 200-256) as a substrate (Figure 29).  Cells were 
either mock treated or irradiated, CHK2 was immunoprecipitated, and the kinase activity 
was measured.  In the mock treated samples, B'α did not have any effect on CHK2 kinase 
activity.  However, after irradiation, overexpression of B'α prevented the full activation 
of CHK2. 
 Since mutation of S33/35 to glutamic acid positively affects CHK2 
phosphorylation primarily on S19, the effect on CHK2 kinase activity was also examined 
since phosphorylation of this site has been shown to enhance CHK2 activity (16).  
HCT15 cells expressing myc-tagged CHK2 WT, D347A, S33/35A, or S33/35E were 
exposed to IR or mock treated.  CHK2 activity was determined using an in vitro kinase 
assay with GST-Cdc25C (amino acid residues 200-256) as a substrate (Figure 30).  In 
the mock treated samples, S33/35E had higher kinase activity than CHK2 WT, whereas 
S33/35A had lower kinase activity.  After IR, S33/35E had slightly higher kinase activity 
than CHK2 WT, while the S33/35A mutant had significantly less.   These data suggest 
that phosphorylation of S33/35 is important for CHK2 activity and that mimicking this 
phosphorylation can increase CHK2 activity even in the absence of DNA damage.   
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Figure 29.  B'α overexpression negatively affects CHK2 kinase activity.  293T cells 
expressing FLAG-B'α or FLAG (as a negative control) were irradiated with 20 Gy and 
incubated for 1 h.  Whole cell lysates were immunoprecipitated using a CHK2 antibody 
and incubated in an in vitro kinase assay using GST-Cdc25C (amino acids 200-256) as a 
substrate.  Autoradiographs (top panel) were normalized against the levels of CHK2 
protein per sample and represented by graphs (bottom panel).  100% activity was defined 
by the amount in the negative control sample after IR.   
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Figure 30.  Mutation of CHK2 serines 33 and 35 affects CHK2 kinase activity.  
HCT15 cells were transiently transfected with empty vector (vector), CHK2 WT, 
S33/35A, or S33/35E and mock-irradiated or exposed to 20 Gy IR and incubated for 1 h.  
Cell lysates were immunoprecipitated and incubated in an in vitro kinase assay using 
GST-Cdc25C (amino acids 200-256) as a substrate (top panel).  Five experiments were 
plotted on a single graph (bottom panel).  Activity of 1 was defined as the activity in the 
CHK2 WT mock-treated sample.  The median of each set of data points is shown with a 
black bar. 
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Mutation of CHK2 Serines 33 and 35 Affects Protein Stability 
 Another mode of CHK2 regulation is via its protein stability.  CHK2 that is 
expressed in HCT15 cells is phosphorylated at S456 after irradiation, stabilizing the 
protein (75).  Since we have shown that phosphorylation of S33/35 affects CHK2 kinase 
activity, we also investigated the role it may play in protein stability.  HCT15 cells 
transiently expressing CHK2 WT, D347A, S33/35A, or S33/35E were incubated with 
cycloheximide to prevent the synthesis of new proteins.  Cells were then either exposed 
to IR or mock treated and collected every two hours (Figure 31A).  By plotting the best-
fit line for each data set, the slope of the line could be examined to measure how fast the 
protein is being degraded (Figure 31B).  In mock treated cells, the S33/35E protein was 
substantially more stable than WT.  S33/35A had a slightly stabilizing effect as well.  
After exposure to IR, the WT protein became more stable, whereas the stability of the 
S33/35A and S33/35E proteins remained similar to the mock treated samples.  These 
results denote the importance of phosphorylations of S33/35 in the increase of CHK2 
stability after IR. 
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Figure 31A.  Mutation of CHK2 serines 33 and 35 affects CHK2 protein stability.  
HCT15 cells were transiently transfected with CHK2 wild-type (WT), S33/35A, or 
S33/35E in the pcDNA3 vector.  100 µg/mL cycloheximide was added to all cells which 
were then either mock treated or exposed to 20 Gy IR and collected at the indicated time 
points.  Levels of each protein were analyzed by immunoblotting.   
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Figure 31B.  Mutation of CHK2 serines 33 and 35 affects CHK2 protein stability.  
Levels of CHK2 proteins from Figure 31A were normalized against the 0 h sample for 
each condition and the best fit line was plotted for each data set.  The slope of the mock 
treated CHK2 WT line is -0.1250, S33/35A is -0.0831, and S33/35E is -0.0443.  The 
slope of the IR CHK2 WT line is -0.0733, S33/35A is -0.0738, and S33/35E is -0.0457.  
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DISCUSSION 
 After DNA damage, the cell must activate cell cycle checkpoints to allow time to 
repair the breaks, or if the damage is too extensive, trigger apoptosis signaling (214).  
ATM phosphorylates CHK2 on multiple sites in the SQ/TQ domain, leading to full 
CHK2 activation (3, 16, 79, 83, 113, 119, 124, 200).  Here, we propose a novel 
mechanism for CHK2 regulation in which ATM phosphorylation causes a dissociation of 
PP2A from CHK2, thus allowing CHK2 activation.  PP2A can then bind to CHK2 hours 
later, providing a mechanism for CHK2 down-regulation after DNA damage (Figure 32). 
 We have identified the B'α subunit of PP2A as a CHK2-interacting protein via a 
yeast two-hybrid screen and have confirmed the interaction in mammalian cells.  Full 
length CHK2 was found to bind to B'α amino acids 89-322.  Our inability to further 
narrow down the interacting region suggests that residues that mediate the interaction are 
scattered within this region. Interestingly, the structure of the PP2A holoenzyme indicates 
that the majority of interactions between the B' subunit and the A and C subunits are 
mediated by amino acid residues located at intervening loops between the 18 α-helices 
(25, 201).  Thus, it is likely that this may also be the case for the interaction with CHK2.  
Identification of these residues could reveal the basis for substrate specificity of PP2A 
enzymes containing different B' subunits.  This large portion of B'α that binds to CHK2 
is a highly conserved region between the B' family members (42).  Indeed, when we 
tested the specificity of CHK2 for the B' family, we found that CHK2 could bind to B'β, 
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B'δ, B'ε, and B'γ3 as well and all of the interactions were dissociated upon exposure to 
irradiation.   
 In mammalian cells, binding between B'α and CHK2 is markedly decreased by 
exposure to IR.  However, other types of damage caused by UV, HU, or MMC did not 
disrupt binding.  Doxorubicin had an effect, but not to the extent to which IR did, 
although comparisons of agents with different mechanisms of action are challenging.  B'α 
can also bind CHK1, though the interaction is not disrupted by any of the DNA damage-
inducing agents tested.  This demonstrates a unique aspect of the relationship between 
CHK2 and B'α: there is binding under normal conditions, but this is disrupted only after 
DSB induced by IR, when serines 33 and 35 are phosphorylated.  CHK2 and B'α are able 
to re-associate hours after IR, and this correlates with the dephosphorylation of S33/35, 
but not with repair of the bulk of damaged DNA as measured by phosphorylation of 
histone H2AX.   
 We have found that maximal dissociation between CHK2 and B'α correlates with 
maximal phosphorylation of CHK2 S33/35, which are phosphorylated in an ATM-
dependent manner (16).  When we inhibited ATM with wortmannin, the phosphorylation 
of S33/35 was prevented as well as the dissociation between CHK2 and B'α.  The region 
in CHK2 that binds to B'α is comprised of amino acids 1-107, which contains the entire 
SQ/TQ domain.  Serines 33 and 35 are located in this domain, suggesting that the 
phosphorylation of these sites could directly contribute to the dissociation of the two 
proteins.  We therefore mutated CHK2 S33/35 to alanine to prevent phosphorylation 
(S33/35A) or to glutamic acid to mimic phosphorylation (S33/35E) and tested the effects 
on binding to B'α.  Our data indicates that phosphorylation at S33/35 is necessary for the 
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dissociation of B'α and CHK2, but it is not sufficient on its own; other phosphorylation 
sites are probably involved as well.  Interestingly, wild-type CHK2 did not dissociate 
from B'α after IR when they were both overexpressed. This may be because when CHK2 
is overexpressed, it can become activated without DNA damage, allowing for 
dissociation in the absence of DNA damage (3, 200). 
 In mock treated cells, S33/35E had a level of phosphorylation at S19 that was 
comparable to CHK2 WT after IR.  Pharmacologic PP2A inhibition with OA also 
increases phosphorylation at S19.  Alternatively, the S33/35A mutant had slightly less 
phosphorylation after IR compared to CHK2 WT.  The S33/35E mutant also had 
increased kinase activity in mock treated conditions compared to CHK2 WT.  
Conversely, the S33/35A mutant had decreased kinase activity after IR, in agreement 
with a previous study (16).  CHK2 kinase activity is decreased when B'α is 
overexpressed as well. 
 Mutations at S33/35 also altered CHK2 protein stability.  The S33/35E mutant 
was more stable as compared to the CHK2 WT under mock treated conditions.  After 
exposure to IR, the stability of the S33/35A and S33/35E proteins did not change; 
however, the CHK2 WT protein stability increased after IR, in agreement with a previous 
study that demonstrated CHK2 expressed in HCT15 cells is more stable after IR (75).  
Our work demonstrates the importance of phosphorylation of S33/35 in this process.   
 PP2A has already been demonstrated to negatively regulate other DNA damage 
response proteins under various conditions, including ATM, ATR, RPA, H2AX, CHK1, 
and p53, signifying the importance of PP2A in the DNA damage response pathway (27, 
28, 36, 48, 55, 88, 115, 121, 122, 128, 129, 142).  In addition, two previous papers have 
100 
 
implicated a role for PP2A in regulating CHK2.  It was demonstrated that CHK2 can 
phosphorylate B'γ in vitro, increasing PP2A activity towards CHK2 in vitro (40).  In an in 
vitro kinase assay, we found that CHK2 could phosphorylate B'α, however, this did not 
have an effect on PP2A activity or localization.  It has also been revealed that treating 
cells with okadaic acid or incubating CHK2 protein with PP2A affected CHK2 
phosphorylation at T68, in agreement with our results (96).   
 Another mode of CHK2 regulation in humans has been characterized.  The Wip1 
phosphatase has been shown to dephosphorylate T68 of CHK2 which leads to a decrease 
in its kinase activity and ability to induce apoptosis (50, 136).  Interestingly, Wip1 
binding to CHK2 is enhanced by DNA damage, in opposition to the relationship between 
PP2A and CHK2, which are dissociated after IR.  Interestingly, both Wip1 and PP2A B'α 
bind to the SQ/TQ domain of CHK2 (136, 206).  
 Mutations in CHEK2, the gene encoding the protein CHK2, have been associated 
with various cancers.  Since the main role of CHK2 in the cell is to prevent the 
propagation of mutations via activation of DNA damage response cell cycle checkpoints, 
any mutation that negatively affects CHK2 function might increase the likelihood that a 
cell becomes cancerous.  In fact, CHK2 mutations that cause decreased or eliminated 
kinase activity, an inability to bind to substrates, inefficient phosphorylation on T68, 
and/or destabilization of the protein have been identified (46, 85, 158, 169, 199).  These 
mutations are all located in the FHA domain, the kinase domain, or the region between 
these two domains. 
 In the context of the interaction between CHK2 and PP2A, mutations at S33 
and/or S35 that prevent the dissociation of PP2A and CHK2 would also prevent the full 
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activation and stabilization of CHK2.  To date, no mutations of S33/35 have been found 
to be associated with cancer, even though they would negatively affect CHK2 function.  
However, it cannot be assumed that because no mutations have been found specifically at 
S33/35 that phosphorylation at these sites is not affected by mutations located elsewhere 
in the protein.  In fact, the 1100delC and E161del mutations have been shown to exhibit 
inefficient phosphorylation of T68 in response to DNA damage (169).  It will be 
necessary to examine these and other cancer-associated CHK2 mutations for the affect 
they have on the ability of CHK2 to be phosphorylated on S33/35 as well. 
 Not only have no mutations been found at S33/35, but no cancer-associated 
mutations have been found in the entire SQ/TQ domain.  It is not known how a mutation 
in the SQ/TQ domain would affect the structure of the protein or the function of the 
enzyme since this domain is unstructured and has not been crystallized (17).  It is 
possible that mutations in the SQ/TQ domain may prevent the binding of PP2A to CHK2 
under normal circumstances, leading to an inappropriate activation of CHK2 that could 
inhibit cell proliferation even in the absence of DNA damage.   
 Proper regulation of the DDR is important for cell function.  Activation of the 
DDR is necessary to prevent the propagation of mutations that could lead to diseases such 
as cancer. Negative regulation of the DDR is important for the cell to prevent 
inappropriate checkpoint signaling as well as returning the cell to the cell cycle after the 
damage is repaired.  Indeed, the multiple modes of CHK2 regulation, by two 
phosphatases and by regulation of kinase activity and protein stability, may highlight this 
importance.  
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Figure 32.  Model of PP2A regulation of CHK2 through binding and dissociation.  
CHK2 binds to PP2A through the B'α subunit under normal conditions.  IR-induced DSB 
causes dissociation through ATM phosphorylation of CHK2 S33/35.  When these are 
dephosphorylated, PP2A can bind back to CHK2 and dephosphorylate it.  This leads to 
decreased CHK2 activity and protein stability.  
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